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ABSTRACT 
 
Mindfulness and Alcohol-Related Problems among Individuals with Fibromyalgia: 
Chronic Pain and Depressive Symptoms as Mediators 
by 
Julie I. Morrissey 
 
Mindfulness is a cognitive attribute that is associated with better health and well-being. 
Fibromyalgia is a neurosensory disorder primarily characterized by chronic pain and comorbid 
depression, leading to an increased risk for alcohol-related problems. Empirical literature 
confirms mindfulness has beneficial associations with chronic pain, depression, alcohol-related 
problems, and fibromyalgia. Mindfulness may lead to better health and well-being by facilitating 
self-monitoring, objective reperceiving, and purposeful changing of health-related behaviors. It 
was hypothesized that higher levels of mindfulness would be related to lower levels of chronic 
pain and depressive symptoms, and, in turn, to fewer alcohol-related problems among 
individuals with fibromyalgia. Cross-sectional data was collected from 287 participants, and 
statistically analyzed using parallel mediation models. Hypotheses were only partially supported; 
mindfulness had an inverse relationship with alcohol-related problems, as hypothesized, although 
the relationship was not mediated by chronic pain or depressive symptoms.  
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CHAPTER 1 
INTRODUCTION 
Research has shown that individuals with fibromyalgia are at an increased risk for self-
management of or coping with their chronic symptoms through alcohol use; and, in turn, this 
may lead to numerous alcohol-related problems (Askay, Bombardier, & Patterson, 2009; Patten 
et al., 2005). Individuals with fibromyalgia are also likely to have a high comorbidity of 
depressive symptoms. Prior research has identified a positive biopsychological feedback 
mechanism that ensues when an individual suffers from chronic pain, as is common in 
fibromyalgia (Díaz-Marsa et al., 2011), coupled with depression (Patten et al., 2005). Indeed, the 
combination of chronic pain and depressive symptoms engender the potential for an exacerbation 
of poor health by the cyclical and compounding system of physiological and psychological 
distress. Currently, effective treatments for fibromyalgia are limited (Wolfe et al., 2010; Wolfe et 
al., 2013). Thus, individuals with fibromyalgia who experience a physiopsychological nexus of 
distress have a greater clinical need for effective medical and psychological treatments.  
Mindfulness may be a protective factor that modulates the subjective experience and 
intensity of chronic pain and depressive symptoms (Kabat-Zinn, 1994) and may abate alcohol-
related problems (Fernandez, Wood, Stein, & Rossi, 2014; Segal, Williams, & Teasdale, 2013). 
Mindfulness is defined as a cognitive attribute that is characterized by moment-to-moment 
purposeful and focused awareness (Brown & Ryan, 2003; 2004; Kabat-Zinn, 1982; 1994). 
Substantial research has identified a salutary relationship between mindfulness and psychological 
and physical well-being (e.g., Baer, Lykins, & Peters, 2012; Brown & Ryan, 2003; Carmody & 
Baer, 2008; Didonna, 2009; Greeson, 2009; Webb, Phillips, Bumgarner, & Conway-Williams, 
2013; Weinstein, Brown, & Ryan, 2009). Independently, the inverse associations between 
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mindfulness and chronic pain (Kabat-Zinn, 1994; Zeidan et al., 2011), between mindfulness and 
depressive symptoms (Hofmann, Sawyer, Witt, & Oh, 2010; Segal et al., 2013), and between 
mindfulness and alcohol-related problems (Fernandez et al., 2014) is well supported in the 
empirical literature. As an adaptive cognitive attribute, mindfulness incorporates such elements 
as the self-monitoring of thoughts and the self-regulation of affect and behavior, which facilitate 
positive health behaviors that cultivate better overall health-related quality of life (Bishop et al., 
2004; Brown & Cordon, 2009; Shapiro, Carlson, Astin, & Freedman, 2006; Webb et al., 2013). 
Nevertheless, the interrelationships between mindfulness, the physiopsychological system of 
distress produced by chronic pain and depression, and alcohol-related problems, particularly 
among those with fibromyalgia, are understudied and not well understood.  
Fibromyalgia 
Fibromyalgia is a chronic and debilitating neurosensory disorder that is primarily 
characterized by widespread chronic pain (Díaz-Marsa et al., 2011). In the 1800s, fibromyalgia 
was first described as a form of muscular rheumatism; yet, the current diagnostic criteria were 
not available until 1990, and it was not until 2005 that the first treatment guidelines for 
fibromyalgia were published (American Pain Society, 2005). Those with fibromyalgia frequently 
experience prolonged periods of lethargy, fatigue, persistent sleep difficulties, and nonrestorative 
sleep. Moreover, those with fibromyalgia commonly experience physical and psychological 
comorbidities such as chronic fatigue syndrome, irritable bowel syndrome, central sensitivity 
syndromes (i.e., temporomandibular disorder, restless leg syndrome, or multiple chemical 
sensitivity), mood disorders, anxiety disorders, or personality disorders (Lauche, Cramer, Dobos, 
Langhorst, & Schmidt, 2013; Lawrence et al., 2008; Singh, 2012).  
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Fibromyalgia currently can only be treated, but not cured, and is exhibited as 
physiological, neurological, cognitive, and psychological health symptoms. The diversity of 
symptoms has highly detrimental effects on quality of life among those with fibromyalgia and 
can encumber an individual’s daily functioning by limiting physical activity, and restricting 
familial and social involvement (Marcus & Deodhar, 2011a; Parra-Delgado & Latorre-Postigo, 
2013). Males, females, adults, and children can develop fibromyalgia. A race predilection has not 
been identified, although for unknown reasons, approximately 90% of those diagnosed with 
fibromyalgia are adult Caucasian females (Lawrence et al., 2008). While it affects approximately 
5 million U.S. adults, the current prevalence among females is reported at 3.4% and 0.5% among 
males (Castro‐Sánchez et al., 2012; Lawrence et al., 2008; Jones et al., 2015). Due to an active 
debate about the etiology of fibromyalgia - whether it develops via a biophysiological origin or is 
a psychosomatic disorder - it is theorized that the actual prevalence rate of fibromyalgia is higher 
than currently documented (Wolfe et al., 2010).  
The etiology of fibromyalgia is undetermined based on disputation regarding what causes 
fibromyalgia to develop; however, it is thought that fibromyalgia does not result from a single 
factor or event, rather from various etiological mechanisms (Parra-Delgado & Latorre-Postigo, 
2013). Etiological risk factors for fibromyalgia, generally, but loosely, are associated with 
biological factors such as a hereditable predisposition, epigenetic mechanisms, or perhaps 
physiological influences such as repetitive injuries to the body, prolonged severe infections or 
viruses, or obesity (Jones et al., 2015; see also Redelmeier, Zung, Thiruchelvam, & Tibshirani, 
2015). Further deliberation proposes that environmental influences may cause fibromyalgia by 
physical insult to the body (e.g., exposure to heavy metal toxins, carcinogenic chemicals ingested 
from food or absorbed from air or water pollution, or perhaps malnutrition) (Marcus & Deodhar, 
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2011a; Parra-Delgado & Latorre-Postigo, 2013). In addition, it is thought that psychological 
factors such as traumatic or stressful events (e.g., physical, sexual, or emotional abuse), or 
untreated psychiatric or psychological disorders may cause fibromyalgia.  
Researchers have acknowledged that inconclusive results of the etiology hinder the 
understanding of fibromyalgia, as well as the prognosis of those with the disorder; inadvertently 
leaving many with fibromyalgia with few effective forms of treatment (Wolfe et al., 2010, 2013). 
Thus, the validity of fibromyalgia as a unique clinical entity is a matter of contention due to no 
discrete diagnostic boundary separating and differentiating the symptomatic overlap of 
fibromyalgia, chronic fatigue syndrome, certain chronic pain disorders or rheumatoid disorders 
(Goldenberg, Burckhardt, & Crofford, 2004; Kanaan, Lepine, & Wessely, 2007).  
Chronic pain. Chronic pain is defined as episodic or continuous sensations of pain that 
persist for more than 6 months and that exceed typical recovery time (Brook, Pickering, & 
Connell, 2011). Pain is felt as an unpleasant sensory experience associated with potential or 
actual bodily injury (Mirchandani, Saleeb, & Sinatra, 2011). Chronic pain may be exhibited 
physiologically as either a symptom (e.g., as with fibromyalgia) or a condition (e.g., lower back 
pain) (Lawrence et al., 2008). Pain is experienced via the multiple interactions between, and 
among, (1) the neurons in the neurosensory system; and, (2) the pain reception centers in the 
brain (Garland & Black, 2014; Perl, 2007). Moreover, pain is generally considered a 
manifestation of multiple malfunctions in the neural network, predominantly among the 
neurosensory mechanisms (Grass, 2011; Riddle, Kong, & Fitzgerald, 2011). Chronic pain has 
been shown to affect one’s physical strength, sensory system, reflexes, and general functioning 
(Leo, Quinton, & Ebert, 2011). Importantly, physiological, psychological, environmental, and 
social factors may magnify one’s subjective experience of pain (Kabat-Zinn, 1994). In any form, 
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chronic pain has long been documented as a common, yet, debilitating factor of many illnesses 
(Leo et al., 2011), such as fibromyalgia, multiple sclerosis, trigeminal neuralgia, complex 
regional pain syndrome, and cervical and lumbar radiculopathies (American Pain Society, 2005; 
Grass, 2011; Vadivelu & Urman, 2011).  
For chronic pain specifically associated with fibromyalgia, it is postulated that the 
experience of pain may be derived from a neurosensory disorder causing peripheral sensitization, 
hyperalgesia, and allodynia (Mirchandani et al., 2011). Individuals with fibromyalgia frequently 
experience chronic polymodal pain as acute or generalized muscle or skeletal pain (Marcus & 
Deodhar, 2011b). Pain is characterized by joint tenderness and discomfort, muscle spasms, 
numbness, tingling, paresthesia, and burning and/or cold sensations throughout the body 
(Lawrence et al., 2008). Pain symptoms also may be accompanied by sensitivity to temperature, 
touch, light, or sound that may also secondarily produce headaches or migraines, or increased 
pain during menstruation (Lawrence et al., 2008). Current literature has recommended 
polypharmacy for the treatment of fibromyalgia pain (e.g., muscle relaxants, antidepressants, 
anticonvulsants, narcolepsy medications, anti-inflammatory medications, and opioids) (Wolfe et 
al., 2013). Yet most pharmacotherapeutic recommendations differ from what the leading 
agencies that formulate treatment guidelines (i.e., American Pain Society, European League 
against Rheumatism, etc.) consider effective medications for fibromyalgia (Wolfe et al., 2013). 
Indeed, most recommended pharmacotherapies do not effectively produce a "clinically important 
change" to fibromyalgia pain symptoms (Wolfe et al., 2013, p. 585).  
Pharmacotherapy and substance use. Fibromyalgia is classified as a chronic pain 
disorder (Lawrence et al. 2008). Opioids are the most common pharmacotherapy used to treat 
chronic pain (Fox III, Hawney, & Kaye, 2011; Sanders, Sprintz, Ellender, Sabartinelli, & Kaye, 
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2011), and it is reported that almost 50% of those with fibromyalgia are treated with opioids for 
pain (Wolfe et al., 2013). Yet, many individuals with fibromyalgia are unsatisfied with opioid 
pharmacotherapy for chronic pain (Wolfe et al., 2013), and dislike the adverse side effects (e.g., 
confusion, constipation, sedation, addiction, etc.) (Berger, 2011). In an effort to provide more 
efficacious and effective treatments for individuals with chronic pain, one study tracked the long-
term effectiveness of opioids for up to 15 years. The study found that only approximately one-
third of individuals reported that their pain symptoms were adequately managed by opioids 
(Gardner-Nix, 2003). Based on data from fjona national, longitudinal study lasting 11 years, 
Wolfe and colleagues (2013) found no clinical benefit for using non-central acting analgesic 
medications, such as opioids, for the adequate treatment of fibromyalgia pain. When seeking to 
manage pain, The Rule of Double Effect obligates practitioners to relieve suffering caused by 
pain (Berger, 2011). This standard, which is an ethical statement from the teachings of Thomas 
Aquinas, asserts that (Berger, 2011): 
An action having two effects, one good and one bad, is permissible if five conditions are 
fulfilled: 1) The act itself is good or at least morally neutral, e.g., giving morphine to 
relieve pain; 2) Only the good effect is intended (relieving pain) and not the bad effect 
(killing the patient); 3) The good effect is not achieved through the bad effect (pain relief 
does not depend on hastening death); 4) There is no alternative way to attain the good 
effect (pain relief); [and] 5) There is a proportionately grave reason for running the risk, 
e.g., relief of intolerable pain. (p. 631)  
Thus, Vadivelu, Urman, and Hines (2011) argued that the use of opioid pharmacotherapy 
for fibromyalgia pain is inappropriate due to detrimental, compounding side effects that simply 
outweigh any benefits. Indeed, empirical evidence and clinical experience demonstrates that for 
 15 
 
individuals with fibromyalgia chronic pain, the long-term use of opioid pharmacotherapy often 
leads to increased pain from opioid-induced hyperalgesia and a marked susceptibility for 
substance abuse. Lack of sufficient treatments also increases the risk of addiction and substance-
related problems (Berger, 2011; Singh, 2012).  
Those with chronic pain, even those who have no history of substance abuse, may 
become psychologically and physiologically dependent on opioids due to the high abuse liability 
(Garland, 2014; Garland & Black, 2014). The chance of developing an opioid misuse problem 
significantly increases, however, when the individual has a personal history of alcohol-related 
problems or mixes alcohol with opioid medications (Murphy et al., 2015). The prevalence of 
substance abuse among those with pain conditions or illnesses characterized by chronic pain is 
greater than the general population – with substance abuse being reported among those with 
chronic pain at up to 23%, versus up to 19% among the general population (Singh, 2012). Pain 
and alcohol-related problems also frequently co-occur; it is not uncommon for individuals with 
chronic pain to mix pain medications with alcohol (Savage, Kirsh, & Passik, 2008). Individuals 
who mix alcohol with pain medications may further complicate the treatment of their chronic 
pain (Savage et al., 2008), and increase the likelihood to develop substance-related problems 
(e.g., substance-induced hyperalgesia, allodynia, or neuropathies) (Egli, Koob, & Edwards, 
2012).  
The detrimental effects of mixing pain medications and alcohol are highly dangerous. 
Alcohol interferes with the way that the body metabolizes opioids, potentially releasing a toxic 
dose of opioids in the body (Murphy et al., 2015). However, at greatest risk to develop alcohol-
related problems are individuals with chronic pain who mix pain medication with alcohol and 
who also experience comorbid depressive symptoms (Savage et al., 2008). Indeed, Pettinati and 
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Dundon (2011) stress that, “there are real concerns about [depression-related] medication 
interactions with alcohol in patients who [are] still drinking” (p. 1).  
Depressive symptoms. Importantly, individuals with fibromyalgia commonly report that 
the experience of chronic pain is usually associated with depressive symptoms (Marcus & 
Deodhar, 2011c; Singh, 2012). Literature suggests that such depressive symptoms may be the 
result of an emotional expression of physical pain (Mirchandani et al., 2011), or from 
psychological distress associated with chronic illness (Patten et al., 2005). Research indicates 
that the combination of chronic pain and depression is often associated with a greater level of 
disability than for those who suffer with either chronic pain or depression alone (Singh, 2012). 
Research has also specified for those with chronic pain, who also develop depressive symptoms, 
a cyclical association emerges (Lauche et al., 2013), suggesting that those with chronic pain may 
have an intensification of comorbid depressive symptoms. 
Depression can interfere with one’s quality of life (Kuyken et al., 2010; 2014; Patten et 
al., 2005). Depression is one way that psychological distress is exhibited (e.g., as sadness, 
hopelessness, helplessness, guilt, shame, or despair). Frequently, individuals experience 
depressive symptoms as changes in eating and weight, sleep difficulties, psychomotor agitation 
or inhibition, difficulty concentrating, rumination, or suicidality – such as suicide ideation, 
behavior, or attempts (American Psychiatric Association, 2013). The underlying causal 
mechanisms of depression are not fully understood. Nevertheless, research reveals that certain 
risk factors such as poor physical and mental health, a negative psychological environment, and 
the quality of one’s social network each contribute to the development of depressive symptoms 
(American Psychiatric Association, 2013).  
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Depression may be acute (e.g., one episode) or persistent (e.g., more than one episode), 
and can be experienced as a primary disorder or a secondary disorder for individuals with 
comorbid disorders. Depression, for example, may be preexisting to substance abuse, yet 
substance abuse may maintain depressive symptoms; whereas, comorbid depression may 
develop as an aspect of substance abuse, as with opioid withdrawal protracted depression (Center 
for Substance Abuse Treatment, 2010). According to Patten and colleagues (2005), it is 
estimated that approximately 60% of individuals who experience one episode of depression will 
subsequently have another depressive episode; furthermore, three out of every four individuals 
who have experienced more than one depressive episode will likely experience another.  
Evaluating the association between depressive symptoms and chronic ill health, Patten 
and colleagues (2005) found that depressive symptoms were highly persistent among those with 
chronic illnesses. The prevalence rate of depression among those with chronic pain (i.e., not 
necessarily associated with a chronic illness) is approximately 50% (Radat, Margot-Duclot, & 
Attal, 2013). An even greater risk for developing comorbid depression was found among 
individuals with chronic illnesses characterized by chronic pain (Bair, Robinson, Katon, & 
Kroenke, 2003).  
Depression has one of the highest comorbidities with fibromyalgia (Patten et al., 2005), 
with a 40% greater prevalence rate among those with fibromyalgia than those with other chronic 
pain disorders (Steiner, Bigatti, & Ang, 2015). Literature indicates that up to 86% of those with 
fibromyalgia suffer from depressive symptoms, and that the severity of depressive symptoms is 
consistently associated with the severity of fibromyalgia symptoms (Parra-Delgado & Latorre-
Postigo, 2013). Of note, individuals may often dismiss depressive symptoms as a normal reaction 
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to chronic ill health (Patten et al., 2005); however, left untreated, depressive symptoms increase 
the likelihood one will develop alcohol-related problems (Zarreen, 2013).  
Alcohol-related problems. The deteriorative nature of alcohol-related problems is 
comparable to depression in terms of persistent chronic symptoms that debilitate daily 
functioning and health (Pettinati & Dundon, 2011). Likewise, both are commonly explained by 
underlying shared environmental or interpersonal etiological factors (Nolen-Hoeksema, 
Desrosiers, & Wilsnack, 2013). Alcohol-related problems may develop as a primary disorder – 
typically producing comorbid disorders, or as a secondary disorder (Center for Behavioral Health 
Statistics and Quality [CBHSQ], 2015). The risk for developing depression is 3.7 times more 
likely when an individual suffers from alcohol use problems (Pettinati & Dundon, 2011). For 
some individuals, depression may be a preexisting disorder that the individual attempts to self-
manage with alcohol, frequently producing comorbid alcohol-related problems (CBHSQ, 2015). 
For others, alcohol-related problems may alter one’s neurological functioning and disturb 
homeostasis, often resulting in comorbid depression (CBHSQ, 2015; see also Pettinati & 
Dundon, 2011). Women are more likely to have preexisting depression with comorbid alcohol-
related problems (Nolen-Hoeksema et al., 2013), whereas men are more likely have alcohol-
related problems that cultivate comorbid depression (Nolen-Hoeksema, 2012).  
Alcohol-related problems can be conceptualized as harmful, hazardous, binge, or heavy 
drinking, and/or alcohol abuse or dependence. Each can include disregard for detrimental 
consequences, the deterioration of one’s quality of life or health, or the perpetuation of comorbid 
conditions due to alcohol consumption (American Psychiatric Association, 2013; National 
Institute on Alcohol Abuse and Alcoholism [NIAAA], 2013; World Health Organization 
[WHO], 2001). Annually, an estimated 3.5 million deaths occur worldwide due to alcohol-
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related problems, with almost 100,000 deaths in the United States alone (NIAAA, 2013). When 
an individual chronically engages in problematic drinking, it is marked by increased frequency 
and quantity, impaired control over drinking, and possible alcohol dependence. According to the 
NIAAA (2013), it is recommended that if individuals consume alcohol, to do so moderately. For 
females, this is one drink or less per day, and for males, two drinks or less per day. The 
guidelines also consider heavy or harmful drinking to be 5 or more drinks per occasion during 5 
or more days per month, and hazardous binge drinking to be the consumption of 4 or more drinks 
for females and 5 or more drinks for males within 2 hours. Heavy and binge drinking are notably 
detrimental to one’s health and well-being. Alcohol-related problems include, but are not limited 
to, engagement in unsafe sex, academic, work, legal, and social problems, increased risk for 
illness, and even death (NIAAA, 2013; see also WHO, 2001).  
Alcohol-related problems may arise as an individual’s attempt to cope with or self-
manage depressive and/or chronic illness symptoms. Empirical studies have documented the 
association between depressive symptoms and alcohol-related problems, and those with 
depression have a greater likelihood to develop alcohol-related problems (Zarreen, 2013). 
Moreover, alcohol is a method used by many individuals who attempt to self-manage symptoms 
of fibromyalgia, such as chronic pain or depression (Kim et al., 2013).  
Chronic pain and depressive symptoms among those with Fibromyalgia, and 
alcohol-related problems. The controversy surrounding the etiology, course, and prognosis of 
fibromyalgia has led some physicians to describe fibromyalgia as a psychosomatic reaction to a 
stressful life and an unhealthy lifestyle (Wolfe et al., 2013). Individuals with fibromyalgia may 
suffer physical and psychological pain needlessly due to uncertainty among physicians regarding 
whether fibromyalgia is, in fact, an actual physical illness (Askay et al., 2009). Indeed, the 
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invalidation of fibromyalgia as a neurosensory disorder often leads to inadequate medical and 
clinical treatment of chronic pain and comorbid symptoms (Wolfe et al., 2010; Wolfe et al., 
2013), the self-management of symptoms with alcohol, and ultimately, negative health-related 
outcomes (Singh, 2012).  
Paradoxically, physicians are significantly concerned about the addictive nature of 
painkillers, like opioids, and literature acknowledges that alcohol is one method individuals use 
to manage chronic pain, due to the undermedication of their experience of pain, which often 
leads to alcohol abuse (Askay et al., 2009). Many individuals with fibromyalgia and comorbid 
depressive symptoms indicate that they felt powerless to control their health outcome and well-
being (Malin & Littlejohn, 2012), and such feelings are associated with the increased probability 
that an individual will use alcohol to manage symptoms (Singh, 2012). Nevertheless, while 
drinking may temporarily buffer pain and distress (Kim et al., 2013) associated with 
fibromyalgia, it also masks an individual’s cognizance of (e.g., awareness and attention to) the 
detrimental physiological and psychological effects associated with alcohol-related problems 
(Askay et al., 2009).  
Alcohol-related problems and sleep difficulties in the context of fibromyalgia. Sleep 
difficulties frequently occur for those with fibromyalgia, with over 25% reporting one symptom, 
and approximately 64% reporting two or more symptoms (Wagner, DiBonaventura, & Chandran, 
2012). Sleep disturbances are often linked with pain symptoms, emotional distress, restless leg 
syndrome, and fibromyalgia sleep-disorder breathing (Lauche et al., 2013). Sleep issues have an 
impact on health-related quality of life (Wagner et al., 2012). Commonly, individuals report that 
when sleep is non-restorative, it leaves the individual feeling fatigued, mentally inattentive, 
irritable, distressed, or experiencing increased pain (Lauche et al., 2013) Although sleep 
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difficulties and pain experiences are associated, the nature of how sleep disturbances increase 
pain is not well understood (Carney et al., 2007). Further research is needed to understand the 
nature of the relationship between chronic pain and sleep difficulties, and to develop effective 
treatments that can improve both pain symptoms and sleep disturbance. In sum, chronic pain 
makes sleep more difficult and sleep difficulties exacerbate pain (Lentz, Landis, Rothermel, & 
Shaver, 1999).  
Similarly, the relationship between depression and alcohol-related problems is well 
established (Bolton et al., 2009; Nolen-Hoeksema et al., 2013; Pettinati & Dundon, 2011), as is 
that many individuals use alcohol to self-medicate emotional distress (Bolton, Robinson, & 
Sareen, 2009). Notably, alcohol consumption often has detrimental implications for sleep 
quality. Ebrahim, Shapiro, Williams, and Fenwisk (2013) conducted a study, which confirmed 
that any amount of alcohol caused a reduction in sleep onset latency, increased sleep disruptions, 
and significantly reduced restorative REM sleep. Comparably, researchers Roehrs and Roth 
(2001) studied the effects of alcohol in relation to sleep quality indicating that alcohol reduced 
rapid eye movement (REM), which had direct effects on daytime fatigue, diminished alertness, 
and shortened attentional focus. Nevertheless, alcohol is often used to induce sleep by dulling 
symptoms that disrupt sleep (i.e., emotional distress, and chronic pain) (Roehrs & Roth, 2001). 
Their findings show that individuals who use alcohol to self-medicate sleep difficulties were able 
to induce sleepiness. However, using alcohol in this way is more likely to result in alcohol-
related problems, and in the long-term, negated any benefits in sleep quality that the alcohol use 
may have temporarily achieved. 
Pharmacotherapeutics are often utilized to treat sleep problems among those with 
fibromyalgia. Staud (2011) studied the effects of a narcolepsy medication on symptoms of 
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fibromyalgia and it was shown to reduce pain and fatigue symptoms, as well as sleep 
disturbances. However, the U.S. Food and Drug Administration (FDA) rejected the drug in 2010 
to treat fibromyalgia on the grounds that it has similar drug effects to the date rape drug gamma-
Hydroxybutyric acid (Staud, 2011). Thus, the risks of potential drug misuse and related problems 
were deemed to outweigh any medical benefits. Wolfe and associates (2013) and Vadivelu, et al., 
(2011), in regards to opioid treatment for pain symptoms of fibromyalgia, stated a similar 
argument – harm does not outweigh benefits, nevertheless, opioids have FDA approval. 
Health care utilization. Fibromyalgia symptoms notably are not effectively managed 
through health care provision due to limited effective treatments being available, and this 
limitation has been well-documented (Wolfe et al., 2013). This suggests that health care 
utilization is often not constructive. Some physicians think health care services are not 
constructive and treatments are ineffective due to fibromyalgia being perceived as an 
unsubstantiated diagnosis. For instance, professional views, such as Ehrlich stated (2003, p. 
1666), continue to perpetuate the controversy surrounding treating fibromyalgia:  
The sooner we abandon the diagnosis, fibromyalgia, disband the patient advocacy 
organizations, and stop the irresponsible publications, the better we serve the public. Is it 
any wonder that most treatments, at least the drugs and the obscene neurosurgical 
interventions, do not really work? One cannot really treat non-diseases.  
Similarly, Hadler conceptualized fibromyalgia as “the medicalization of misery” (2003, p. 1668-
1670), and stated:  
The medical contract demands specific treatment for the cause of the pain. Such a 
treatment act rests on the shakiest of scientific grounds for the patient with a regional 
musculoskeletal disorder. It is groundless for the patient with persistent widespread 
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pain…       The proponents of the fibromyalgia construction are convinced that their 
pathophysiological insights and theories are valid, albeit as yet unproved, and their 
therapeutic approaches need but tweaking to produce the benefit that has eluded 
demonstration to date. 
Thus, the validity of fibromyalgia as a unique clinical entity is a matter of great 
contention. Tense discussions have advanced into a heated controversy due to no discrete 
diagnostic boundary of fibromyalgia symptoms. Furthermore, health care providers are calling 
for a separation and differentiation of the symptomatic overlap of symptoms commonly 
associated with fibromyalgia and other health conditions including chronic fatigue syndrome, 
certain chronic pain disorders, and rheumatoid disorders (Goldenberg et al., 2004; Kanaan et al., 
2007).  
Ineffective management of pain symptoms also increases sleep difficulties (Carney, 
Edinger, Manber, Garson, & Segal, 2007), and sleep problems increase pain sensitivity (Carney 
et al., 2007), depressive symptoms (Savage et al., 2008), and greater use of health care services 
(Manocchia, Keller, &Ware, 2001). This suggests that a cycle of inadequate management of 
symptoms, the maintenance of debilitating pain sensation and depression symptoms, poor sleep 
quality, and unsatisfactory outcomes from health care treatments have implications for alcohol-
related problems (see Carney et al., 2007; Roehrs & Roth, 2001; Savage et al., 2008; Singh, 
2012; Zarreen, 2013). According to Savage and colleagues (2008), there exists a synergy of pain 
and alcohol-related problems that include sleep disturbances, psychological distress such as 
depression, and increased functional disability. These findings suggest the need for an 
intervention that improves multiple symptoms. 
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In sum, fibromyalgia is a complex neurosensory disorder leading to high health care 
utilization; yet, it remains very difficult to treat. Common and exacerbating sequelae of 
fibromyalgia include pain sensitivity, depressive symptoms, and sleep difficulties, and the 
potential for self-medication with alcohol, and its attendant risks. As such, it is important to find 
consistently effective treatments for fibromyalgia and the compounding debilitation these 
comorbid symptoms and conditions produce.  
Mindfulness 
For centuries, spiritual and religious practitioners have advocated the benefits of 
mindfulness (Brown & Cordon, 2009). The psychological construct of mindfulness was derived 
from the Buddhist tradition of the Noble Eightfold Path; however, in Western adaptations, it 
tends to be construed as nonspiritual and nonreligious (see Brown & Ryan, 2003; Christopher, 
Christopher, & Charoensuk, 2009; Marlatt & Kristeller, 1999). In psychological science, 
mindfulness is considered a cognitive practice that includes distinctive features of consciousness 
that are employed by one’s present attentive self-awareness, such as sustaining attention on 
fluctuating stimuli, monitoring events as they arise, emotionally detaching from those events 
without reaction, and redirecting one’s attention (Brown, Ryan, & Creswell, 2007; Zeidan et al., 
2011). Brown and Ryan (2003) argue that the attribute of consciousness that augments “well-
being is mindfulness” (p. 822; emphasis in original).  
Furthermore, Shapiro and colleagues (2006) delineate mindfulness with three axioms – 
attention, intention, and attitude – that constitute a meta-mechanism of action by which health is 
thought to be enhanced. Attention involves suspending judgment and the interpretation of 
experience(s) while actively perceiving. Intention regulates thoughts, emotions, and behavior by 
allowing one to be more adaptive and flexible to change. Both perception and intention affect 
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one’s attitude (which is the quality of one’s attention, such as positive or negative), which then 
affect one’s mood from moment to moment. Conceivably, re-perceiving with purposeful intent 
and a non-judgmental attitude bolsters health by, “(1) self-regulation and self-management, (2) 
emotional, cognitive, and behavioral flexibility, (3) values clarification and, (4) exposure” 
(Shapiro et al., 2006, p. 380).  
Ideally, the implementation of mindfulness may be used to bolster well-being and treat or 
manage various psychological and physical symptoms (Riley & King, 2009). Despite the general 
enthusiasm among researchers regarding the potential therapeutic role of mindfulness, one 
limitation among research is the lack of a universal conceptualization of what mindfulness 
entails (Bishop et al., 2004). Even with considerable overlap between the various concepts of 
mindfulness, different forms of mindfulness show various associations with health behaviors.  
For example, two studies by Leigh and colleagues (Leigh, Bowen, & Marlatt, 2005; 
Leigh & Neighbors, 2009) indicated that college students who scored higher in some aspects of 
mindfulness (i.e., mind/body awareness) used more alcohol and tobacco than those low in 
mind/body awareness. This is unexpected given other evidence showing that enhancing 
mindfulness (i.e., objective observation, attention to thoughts, feelings, and reactions) can be a 
means to reduce alcohol-related problems (e.g., Pearson, Brown, Bravo, & Witkiewitz, 2015). As 
such, the relation between mindfulness and alcohol use may depend on which aspects of 
mindfulness are being examined.  
To better clarify research findings and clinical implications, clinicians and researchers 
have progressively conceptualized variations of mindfulness as a state, trait, or the systematic 
process of finding equilibrium of stimuli by cultivating insight into thoughts, feelings, and 
behaviors (Bishop et al., 2004). Accordingly, a state form of mindfulness is viewed as situational 
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or temporary mindfulness; that is, a transitory state that does not require one volitionally to 
engage in mindfulness, yet appears extemporaneously and occurs variably on a spectrum of 
intensity and frequency as a response to a particular situation (Bishop et al. 2004; Brown & Ryan 
2003). Trait mindfulness, in contrast, is a dispositional, innate, or preexisting characteristic that 
is enduring (Brown & Ryan, 2003; 2004). Importantly, individuals may have a capacity to 
cultivate and utilize various innate levels of dispositional mindfulness.  
Related to, but sufficiently distinct from trait mindfulness, is systematic mindfulness. 
Systematic mindfulness is considered a habitual practice (as opposed to an innate disposition in 
the context of trait mindfulness) to refine one’s attention and awareness; in turn, such 
psychological training may result in a refinement of mental states, mental qualities, and insight 
regarding body sensations and feelings (Kabat-Zinn, 1994). This habitual practice enables the 
development of mindfulness as a stable skill (i.e., systematic mindfulness), rather than simply an 
extemporaneous response (i.e., state mindfulness) or a pre-existing tendency (i.e., trait 
mindfulness) (Kabat-Zinn, 2013). The process of systematic mindfulness training is commonly 
associated with devout spiritual or religious practices, such as meditation or prayer (Christopher 
et al., 2009). Systematic mindfulness training is also used in mindfulness-based psychological 
therapies (e.g., Mindfulness-Based Stress Reduction, MBSR; Kabat-Zinn, 1982), and is 
described as cultivating a “way of being” (Kabat-Zinn, 1994, p. 4).  
Researchers have continually documented the effectiveness of trait mindfulness to 
increase well-being (Baer et al., 2012; Brown & Ryan, 2003; Carmody & Baer, 2008; Greeson, 
2009), by its effect on psychological, somatic, and physiological health (Baer et al., 2012; Brown 
& Ryan, 2003; Greeson, 2009; Kabat-Zinn, 2013). Mindfulness-based therapies (MBT) are 
shown to be: (1) effective in treating psychological conditions (e.g., depression, anxiety, 
 27 
 
addictive behaviors, eating disorders, obsessive-compulsive disorder, posttraumatic stress 
disorder, attention deficit hyperactivity disorder, and psychosis) and physical illnesses, in 
conjunction with medical treatment (e.g., diabetes, cardiovascular disease, HIV/AIDS, cancer, 
and psoriasis) (see Kabat-Zinn, 2003; Carlson, 2012; Carlson & Brown, 2005), and, (2) 
appropriate for clinical and inpatient settings, across the lifespan (Didonna, 2009).  
Consistent with clinical research, behavioral neuroscience and neuroimaging research aid 
in the understanding of how mindfulness may influence an individual’s brain functioning and 
structures. Evidence suggests that increased levels of trait mindfulness may alter the activity and 
structure of the brain (Treadway & Lazar, 2009). Several EEG, PET, and fMRI-based studies 
noted changes in the brain due to increased levels of trait mindfulness, and concluded, 
correspondingly, mindfulness may alter the neural networks of cognitive, emotional, and 
behavioral processes (Treadway & Lazar, 2009). Although imaging findings have been 
somewhat inconsistent, continued examination into how mindfulness affects the brain, via 
improving imaging techniques, may provide more insight into the underlying neural mechanisms 
of how mindfulness may have a therapeutic effect on specific disorders or conditions.  
Mindfulness and Health 
The World Health Organization [WHO] comprehensively defines health as “a state of 
complete physical, mental, and social well-being and not merely the absence of disease or 
infirmity” (WHO, 1946, p. 1). Similarly, chronic ill health is defined as the presence of a long-
term health condition, disease, illness, or disorder [such as fibromyalgia], which encompasses the 
subjective experience of living with ill health (Centers for Disease Control and Prevention 
[CDC], 2016). According to the CDC (2016), it is vital for those with chronic ill health to set 
health goals, identify barriers to health, and monitor one’s health. Mindfulness arguably is 
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“highly relevant to a variety of functional outcomes, including health and health-promoting 
behavior” (Webb et al., 2013, p. 236).  
It is thought that if an individual is not mindfully self-aware, an inability to disengage or 
distance one’s self from an associated unhealthy connotation to a specific stimulus may occur 
(Hayes, Strosahl, & Wilson, 2012; Hayes & Wilson, 2003). These unhealthy connotations 
become paired with rigid cognitive rules or judgments that may rouse, prompt, and perpetuate 
maladaptive or distressing thoughts or feelings, or maladaptive behaviors (Cavanagh, Strauss, 
Forder & Jones, 2014). The cognitive self-observational feature of mindfulness can allow an 
individual to detach from harmful or unhealthy thoughts, feelings, or behaviors by re-perceiving 
a situation and, in turn, may alter a person’s behavior by altering one’s affective state (Shapiro et 
al., 2006). In this way, mindfulness may bolster the self-management of health, as well as one’s 
attitude about health and health care (Shapiro et al., 2006), which may contribute to health and 
well-being (Brown & Cordon, 2009).  
Mindfulness and chronic pain. Mindfulness is a protective factor that may decrease 
one’s subjective experience of pain. Mindfulness and pain both alter sensory, cognitive, and 
affective dimensions of one's subjective experience (Zeidan et al., 2011). Discernment among the 
various aspects of pain and one’s subjective experiences of such pain, tends to encourage and 
facilitate appropriate pain management and is associated with a better health and quality of life 
(Garland & Black, 2014; Vadivelu et al., 2011). According to Kabat-Zinn (1994), pain 
differentiation is key to effectively treating chronic pain, and involves an individual better 
understanding and identifying different forms of pain, such as the quality of the pain, the 
duration and frequency, the location and its distribution in certain areas, as well as what 
symptoms are alleviated or aggravated by certain factors. Mindfulness may be an effective tool 
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for individuals experiencing chronic pain to identify and differentiate among the various 
manifestations of their pain.  
Empirical literature indicates that Mindfulness-Based Stress Reduction (MBSR), a 
formalized approach to clinical therapy, can reduce pain severity and the distress associated with 
chronic pain, as well as facilitate the appropriate self-regulation of such symptoms (Kabat-Zinn, 
1982; 1987; 1994). Some of the earliest trials on the therapeutic effects of mindfulness (i.e., 
MBSR) to alter the experience of chronic pain found individuals experienced a bolstered ability 
to cope with and understand sensations of chronic pain (Kabat-Zinn, 1982; 1987; 1994). 
Similarly, research has shown that not only does mindfulness reduce the subjective experience of 
pain, but also, that those who participated in a mindfulness program (MBSR) were less likely to 
control pain with pain medication (Kabat-Zinn, 1985).  
Since these initial studies from more than 30 years ago, many researchers continue to 
evaluate the effect of mindfulness on chronic pain (e.g., Garland & Black, 2014; Lauche et al., 
2013; Morone, Lynch, Greco, Tindle, & Weiner, 2008; Schmidt et al., 2011; Zeidan et al., 2011). 
A more recent study was an eight-week trial, with a 3-month follow-up, of the effects of 
mindfulness on chronic pain (Morone et al., 2008). Results of the trial echoed Kabat-Zinn’s main 
conclusions, such that those who managed their chronic pain with mindfulness techniques 
reported a significant reduction in the severity and sensation of pain over time, along with 
increased attention skills, improved sleep quality, and a better overall feeling of well-being. Such 
studies suggest that increased levels of mindfulness have a direct effect on augmenting one’s 
attention and awareness to negative attitudes and reactions to pain, the acceptance of limitations, 
and a sense of greater well-being by purposefully noticing activities or emotional states that 
aggravated pain. 
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Garland and Black (2014) evaluated current clinical and neuroimaging research to assess 
the effect of mindfulness on chronic pain. They report that there is substantial evidence that 
supports the effect of mindfulness to attenuate pain sensations. Individuals who experienced 
chronic pain, yet had increased levels of mindfulness, were more objective about negative 
attitudes associated with pain, had increased awareness of negative attention given to pain, and 
had augmented attention to how their reactions to pain altered pain sensations. Moreover, the 
way the pain was processed by the brain was altered by mindfulness techniques. Likewise, 
Zeidan and colleagues (2011) assessed the effects of mindfulness on one's experience of pain, 
also evidencing a reduction in chronic pain for individuals with higher levels of mindfulness. 
Indeed, it was evident on fMRI scans that the brain altered how it processed stimuli by changing 
how it differentiated stimuli into one’s subjective sensory, conscious experience.  
Another factor in appropriately managing chronic pain is addressing the high risk of 
developing comorbid depression among those with such pain. Research indicates for those with 
fibromyalgia that depression is an affective experience associated with pain (Riddle et al., 2011), 
and the neuro-markers for both depression and pain cannot be examined in isolation (Campbell, 
Clauw, & Keefe, 2003). Applied to fibromyalgia, research suggests that “neurosignatures for 
pain and depression exist throughout the neuromatrix [e.g., whole person; see Melzack, 1999] 
and that these signatures … persist unless modified by interventions that affect the entire 
network” (Campbell et al., 2003, p. 400).  
Mindfulness and depressive symptoms. Depression is one of the most prevalent and 
debilitating psychopathologies (Patten et al., 2005; Segal et al., 2013). Research continues to 
elucidate ways in which individuals may more effectively manage and treat the painfully adverse 
experiences of depression. Depressive symptoms have a particularly salient association with 
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rumination. Rumination is a perseverative mental cycle in which one dwells on an event, 
thought, or emotional consequence, replaying events in the mind as a repetitive stream of 
negative judgements (Didonna, 2009; Kocovski & Rector, 2007). Rumination is well studied and 
is a substantial contributing factor of depression (Didonna, 2009; Kocovski & Rector, 2007). 
Rumination inhibits an individual from disengaging and detaching from certain thoughts and 
encumbers one’s ability to objectivity consider the past, present, or future (Barnhofer & Crane, 
2009). When a negative thought has a substantial function in driving ruminative processes, it 
may contribute to undesirable moods and the maintenance of depression (Hayes et al., 2012).  
Nolen-Hoeksema (2000) found that those who engage in rumination when depressed 
tended to have longer and more severe episodes of depression. Furthermore, one detrimental way 
individuals managed rumination was by the self-medication of alcohol (Nolen-Hoeksema & 
Harrell, 2002). Indeed, rumination and self-medication with alcohol consistently is highly 
correlated (Nolen-Hoeksema & Harrell, 2002). Data from the National Epidemiologic Survey on 
alcohol and related conditions sampled over 10,000 individuals with depressive symptoms (i.e., 
Major Depressive Disorder, Dysthymia) finding that almost half engaged in self-medication 
(Bolton et al., 2009). This relationship between rumination and self-medication may stem from 
an individual’s attempt to “escape from the self;” that is, to escape ruminative processes (Nolen-
Hoeksema & Harrell, 2002, p. 392).  
However, when such a thought is observed mindfully and objectively reperceived it may 
be experienced as a mental event that will pass, rather than a persistent truth (Teasdale et al., 
2002). Objectively challenging thoughts, judgements, or feelings as to whether something is 
good, bad, neutral, pleasant, tolerable, or unbearable helps individuals better attain and respond 
to experiences with more meaningful insight into negative thoughts and subjective opinions 
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(Kabat-Zinn, 1994; 2007). Negative mental events often lose cyclic momentum (i.e., decreasing 
rumination) as an individual adopts a stance towards experiencing such processes through 
openness, curiosity, and recognition (Hayes & Wilson, 2003).  
Nevertheless, mindfulness is not a tool intended to “eliminate the thoughts that are 
generated, but rather to disidentify oneself from them” (Didonna, 2009, p. 9). There is evidence 
that many individuals who utilize mindfulness experience a beneficial shift in perception – 
realizing that “thoughts are not facts” (Barnhofer & Crane, 2009, p. 237; also see Teasdale et al., 
2002). This form of metacognition highlights that a person is not solely thought-based which, in 
turn, might help individuals with depression disentangle from rumination (Teasdale et al., 2002). 
Indeed, several studies (Kocovski, Segal, & Battista, 2009) carried out with non-clinical and 
clinical samples found that mindfulness training lead to decreased ruminative processes and that 
those decreases accounted for reductions in depressive symptoms. 
Strong empirical and clinical evidence similarly indicate mindfulness contributes to a 
lessening of distress associated with chronic cognitive and physical symptoms (Barnhofer & 
Crane, 2009; Didonna, 2009; Kabat-Zinn, 1994; Segal et al., 2013; Williams, Teasdale, Segal, & 
Kabat-Zinn, 2007). Sephton and colleagues (2007) found mindfulness-based interventions to be 
a noteworthy self-management method for fibromyalgia-induced depression. Mindfulness 
showed favorable outcomes for comorbid chronic pain and depression by increasing sensory 
acuity, decreasing responses to pain, and altering pain-associated neuroactivity, which also have 
significant implications for the reduction of depression (Gardner-Nix, 2009; Kocovski et al., 
2009).  
Understanding the underlying mechanisms of how mindfulness affects the brain, psyche, 
and body is in the early stages; nonetheless, mindfulness techniques have shown substantial 
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effects on neurological, physiological, and psychological factors associated with depression 
(Barnhofer & Crane, 2009) and other chronic illnesses like fibromyalgia (Sephon et al., 2007). 
Researchers continue to elucidate how mindfulness reduces depressive and chronic symptoms as 
well as increases positive health outcomes. Simply, Sephton and colleagues indicated that 
mindfulness interventions hold promise for those with fibromyalgia, “especially when viewed in 
light of the current gaps in medical management of [the] disorder” (Sephton et al., 2007, p. 82).  
When medical treatment is inadequate to alleviate symptoms, individuals with chronic 
illnesses often seek to escape adverse psychophysiological distress through self-medication with 
alcohol (Singh, 2012). Mindfulness often bolsters a positive feeling of management over one’s 
psychological and physical health status through self-reflection and self-monitoring (Brown & 
Ryan, 2003). When an individual feels control over one’s health and health behaviors, this tends 
to augment treatment adherence among those with health ailments (Serxner, 2013). Additionally, 
such mindful awareness to thoughts, feelings and behaviors leads to reductions in rumination 
about poor health, lack of adequate health care, functional limitations, and life difficulties 
associated with chronic symptoms (Nolen-Hoeksema, 1991; Kocovski et al., 2009). In turn, 
decreasing ruminative processes potentially may avert maladaptive coping strategies like the 
utilization of alcohol to self-medicate (Bien, 2009; Fernandez et al., 2014).  
Mindfulness and alcohol-related problems. Considerable evidence has shown that 
mindfulness improves one’s overall quality of life by functioning as an effective coping strategy 
(Fernandez et al., 2014; Song, Lu, Chen, Geng, & Wang, 2014), which aids in the process of 
decreasing alcohol-related problems (Pearson et al., 2015). Bien (2009) argued that addictive 
behaviors, such as alcohol-related problems, are often spurred by the desire to cope with or 
relieve one’s self of the plight of life and all its vicissitudes - that is, the crux of alcohol-related 
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problems is the avoidance of, or escape from, pain (Nolen-Hoeksema & Harrell, 2002). A person 
with problematic alcohol use often experiences the world as an “endless struggle” and alcohol 
seems to provide a solution to equivocate reality by altering the subjective and objective senses 
(Bien, 2009, p. 290). However, this illusionary or temporary escape from reality (i.e., escaping 
from the reality of dealing with chronic symptoms of illness) is short-lived, with excessive 
alcohol use, and its related problems, becoming detrimental to well-being (Bien, 2009).  
Research indicates avoidance of psychological and physical pain is a primary reason why 
many individuals use alcohol problematically (Bien, 2009); in essence, to stop thinking about 
limitations, shut out symptoms of pain, and ignore negative sensations (Bien, 2009; Bolton et al., 
2009; Singh, 2012,). Also, based on the notion internal experiences cannot be eliminated, but 
merely altered (Hayes et al., 2012), accordingly strategies that augment beneficial internal 
experiences improve health and well-being (Hayes & Wilson, 2003). Avoidance maintains 
alcohol-related problems among those with chronic pain and distress; therefore, paying attention 
to and observing symptoms may be more beneficial than detrimental alcohol-based coping 
strategies.  
Regardless of what initial factors contributed to developing problematic alcohol 
consumption, continued excessive alcohol use can produce unhealthy or unrealistic expectations 
of the effects of alcohol consumption (e.g., positive affective states or prosocial behavior will 
increase) (Nolen-Hoeksema & Harrell, 2002). Such expectations can cognitively fuse with the 
judgment that alcohol is an adequate coping strategy (Hayes et al., 2012). Moreover, such 
detrimental expectations or assumptions of the effects of alcohol use may in fact be incredibly 
alluring for those with persistent debilitating symptoms of physical pain or emotional distress. 
This is suggested by individuals with chronic illnesses having a much greater prevalence of 
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alcohol-related problems than the general population (Singh, 2012). Approximately one fourth of 
individuals with chronic pain use alcohol as a means to cope (Singh, 2012), and almost half of 
those with chronic depressive symptoms self-medicate with alcohol (Bolton et al., 2009). 
Furthermore, individuals with comorbid chronic pain and depressive symptoms, such as those 
with fibromyalgia, are at greatest risk for self-medicating with alcohol (Savage et al., 2008). 
Mindfulness is theorized to alleviate alcohol-related problems by increasing self-
awareness of the internal states and triggers for alcohol use, and attention to utilizing a cognitive 
mode through which cravings can be observed without judgment (Pearson et al., 2014). 
Awareness of and attention to ambivalence and decisional conflicts about alcohol-related 
problems could help individuals determine what changes to make to their alcohol use (Miller & 
Rollnick, 2013). Garland, Schwarz, Kelly, Whitt, and Howard (2012) indicated that mindfulness 
is a vital component in undoing reactionary alcohol use. Bien (2009) posited that when one 
utilizes deep awareness to and purposeful attention of the present moment, one has increased 
clarity before revalidating past judgments, automatic thinking, or future worries. An individual 
may thereby enter an intentional perception that repeatedly has been shown to abate behaviors 
that increase alcohol-related problems. 
Statement of the Problem 
Fibromyalgia alters the way a person lives and functions in day-to-day life. Many 
individuals with fibromyalgia endure a broad range of unpleasant and chronically painful 
neurosensory experiences, as well as sleep difficulties, fatigue, gastrointestinal issues, and 
cognitive issues (see Lauche et al., 2013; Lawrence et al., 2008). Individuals with fibromyalgia 
report that is it exceedingly difficult to cope with chronic pain while experiencing fatigue due to 
sleep loss (Carney et al., 2007); suggesting that continual disruption of sleep may deteriorate 
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one’s ability to cope effectively with chronic symptoms. Researchers demonstrated that 
comorbid sleep disturbances in relation to fibromyalgia symptoms (i.e., chronic pain) frequently 
contribute to a more general negative mood and increase the likelihood an individual may 
experience depressive symptoms (Carney et al., 2007). Indeed, studies focusing on illnesses that 
are highly comorbid with sleep disorders, such as fibromyalgia, must statistically account for 
sleep quality in association with depression (Carney et al., 2007). Therefore, evaluating sleep 
quality as a covariate could elucidate mechanisms underlying chronic negative mood states (i.e., 
depression). Research findings indicated that most individuals with fibromyalgia often suffer 
from comorbid depression (Singh, 2012). Indeed, the amalgamation of fibromyalgia and 
depressive symptoms has shown to further decline one’s quality of life by simply making life 
more difficult and limiting (Wolfe et al., 2013). 
Those with fibromyalgia often have trouble treating their symptoms due to the scientific 
community’s limited understanding of its etiology and course, and an extended length of time to 
receive a diagnosis of fibromyalgia - potentially taking years to be diagnosed before treatment 
occurs (Wolfe et al., 2013). Despite some recent advances in the scientific study of fibromyalgia 
(most notably that many medical studies now consistently recognize fibromyalgia as a legitimate 
disorder – see Askay et al., 2009), few adequate treatments are available. As such, those with 
fibromyalgia are left to manage an array of complex and comorbid symptoms with certain 
interventions that are aimed at one symptom, but generally do not produce effects on the other 
symptoms (Wolfe et al., 2013).  
Further, greater utilization of health care services has not always produced beneficial 
results for those with fibromyalgia (Wolfe et al., 2013). Vadivelu et al., (2011) contended that 
the most commonly prescribed treatment – opioid therapy – for fibromyalgia pain is 
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inappropriate due to the detrimental side effects that offset the benefits (i.e., substance abuse risk 
and opioid-induced hyperalgesia). In fact, individuals with fibromyalgia are already at increased 
risk for substance abuse (i.e., illicit drug use or misuse of prescribed opioids) associated with 
chronic pain and depressive symptoms (Center for Substance Abuse Treatment, 2010; Pettinati 
& Dundon, 2011). When combined with insufficient treatment options, this can result in 
individuals supplementing health care or coping with untreated symptoms by self-medicating 
with alcohol (Pearson et al., 2015; Riley & King, 2009).  
Nevertheless, not all those with fibromyalgia use alcohol to cope. While there is scarce 
research evaluating the effects of mindfulness on alcohol-related problems specifically among 
those with fibromyalgia, there is promising evidence that mindfulness may attenuate the 
subjective experience of chronic pain and the intensity of depressive symptoms by enabling one 
to observe, re-perceive, and facilitate better management of symptoms. Mindfulness has been 
demonstrated to treat alcohol use problems effectively when used independently or conjoined 
with other types of health care utilization (Hayes, 2003; Miller & Rollnick, 2013). For those with 
fibromyalgia, mindfulness often facilitates cognitive-emotional resources that enable better 
coping strategies (Shapiro et al., 2006). Higher levels of mindfulness (or the propensity to be 
mindful) also may decrease the likelihood that an individual would engage in compulsive and/or 
habitual self-medication with alcohol as a form of coping (Black, 2014; Garland & Black, 2014; 
Garland, 2013; Riley & King, 2009).  
To date, many studies have evaluated the effect of mindfulness-based techniques (MBTs) 
on chronic pain conditions or depressive disorders (e.g., Barnhofer & Crane, 2009; Gardner-Nix, 
2009; Kabat-Zinn, 1994; 2007; Kocovski et al., 2009; Segal et al., 2013; Teasdale et al., 2002; 
Sephton et al., 2007), as well as the relationship between MBTs and alcohol-related problems 
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(e.g., Bien, 2009; Garland et al., 2012; Hayes et al., 2012; Miller & Rollnick, 2013; Pearson et 
al., 2014). MBTs have also been shown to help those with fibromyalgia improve overall well-
being, and facilitate better coping strategies (e.g., Grossman, Niemann, Schmidt, & Walach, 
2004; Grossman, Tiefenthaler-Gilmer, Raysz, & Kesper, 2007; Kaplan, Goldenberg, & Galvin-
Nadeau, 1993; Parra-Delgado & Latorre-Postigo, 2013).  
However, recently, Parra-Delgado and Latorre-Postigo noted that, “… no research exists 
on the use of these programmes [MBTs] in symptoms of depression and pain in patients 
diagnosed with fibromyalgia” (2013, p. 1016, emphasis added). Parra-Delgado and Latorre-
Postigo proceeded to conduct one of the first studies of this kind. Their study showed that 
Mindfulness Based Cognitive Therapy (MBCT; Segal et al., 2013) facilitated a meaningful 
improvement in individuals with fibromyalgia in regards to how their perception of pain 
sensations and depressive symptoms influenced their quality of life. MBCT helped these 
individuals to be more accepting of the experience of pain and to be aware of associated 
automatic thoughts, which lead to a reduction of depressive symptoms.  
The beneficial effect of MBTs related to chronic pain, depressive symptoms, and alcohol-
related problems in the context of fibromyalgia has not been examined. In particular, the 
components of mindfulness itself and/or the mechanism(s) of association by which this 
improvement could be explained have not received empirical attention. Of note, there is some 
evidence to suggest that while MBTs are associated with beneficial outcomes in general, 
mindfulness itself may not necessarily be the primary active ingredient (see Webb et al., 2013) 
and thus verification of the basic role of mindfulness in association with particular outcomes is 
warranted. In summary, the association of mindfulness with the aforementioned outcomes, 
whether as a trait or state variable, in and of itself, has not been well studied. The present study 
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evaluated the mediational relationship of chronic pain and depressive symptoms, among those 
with fibromyalgia, to better understand the mechanisms of association underlying the 
relationship between trait mindfulness (rather than taught MBTs) and alcohol use problems.  
Hypotheses 
The research question addressed by this study is focused on: What is the relationship 
between mindfulness, chronic pain, depressive symptoms, and alcohol-related problems among 
people with fibromyalgia? See Figure 1 below for a visual representation. Specifically, the 
relationship between mindfulness (independent variable) and alcohol-related problems 
(dependent variable), operating through chronic pain and depressive symptoms (mediator 
variables), among individuals with fibromyalgia, was examined while controlling for drug-
related-problems, sleep quality, and health care utilization. The hypotheses for this study were as 
follows. Among individuals with fibromyalgia: 
1. At the bivariate level of analysis: 
a. Mindfulness would have a statistically significant negative association with 
alcohol-related problems, bodily pain, depressive symptoms, poor sleep 
quality, health care utilization, and drug-related problems.  
b. Statistically significant positive associations would be observed among bodily 
pain, depressive symptoms, poor sleep quality, alcohol-related problems, 
drug-related problems, and health care utilization. 
2. At the multivariable level of analysis, controlling for poor sleep quality, health care 
utilization, and drug-related problems: 
a. Mindfulness would have a direct, statistically significant negative relationship 
with alcohol-related problems, bodily pain, and depressive symptoms.  
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b. Bodily pain and depressive symptoms would have a direct, statistically 
significant positive relationship with alcohol-related problems.  
c. The association of mindfulness with alcohol-related problems would be 
mediated by bodily pain and depressive symptoms. That is, higher levels of 
mindfulness would be associated with lower levels of both bodily pain and 
depressive symptoms that, in turn, would be associated with less alcohol-
related problems. 
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Figure 1. Graphic Illustration of a Parallel Mediation Model    
Note: see Hayes (2013). 
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CHAPTER 2 
METHODS 
The current cross-sectional study is part of a larger study that was conducted and was 
approved by the relevant Institutional Review Board. Participants were recruited (see Table 2 for 
eligible participants’ demographic information) via advertisements distributed to national, 
regional and local organizations, online informational and support groups, and social media 
avenues associated with fibromyalgia. Initially, 579 participants were recruited, and eligible 
participants (n = 287) provided informed consent to participate in a 30 to 45 minute online 
survey (distributed via Survey Monkey) consisting of a variety of self-report questionnaires 
related to health and well-being.  
Measures 
See table 1 below for each key study variable reliability estimate.  
Table 1 
Reliability estimates for Key Variables 
Measures Number of Items Cronbach’s Alpha 
Cronbach’s Alpha Based 
on Standardized Items 
MAAS 15 .899 .899 
DASS: DEP 7 .916 .915 
SF-36: BP 2 .852 .854 
AUDIT-10 10 .602 .768 
DAST-10 10 .716 .759 
MHP-H: HCU 3 .490 .513 
PSQI 1 - - 
 
Note: The closer Cronbach’s alpha (α) is to 1.00 the greater the reliability. George and Mallery (2003, p. 231) 
provide the following rules of thumb: “ > .9 – Excellent,  > .8 – Good, > .7 – Acceptable, > .6 – Questionable, > .5 – 
Poor, and < .5 – Unacceptable”. 
 
 43 
 
Mindful Attention Awareness Scale. Trait mindfulness was assessed using the Mindful 
Attention Awareness Scale (MAAS), a 15-item self-report questionnaire that assesses for core 
attributes of consciousness. Trait mindfulness concerns one’s intrinsic and extrinsic modes of 
perceiving the world. Attributes of trait mindfulness are bare attention and clear awareness that 
form a nexus of being purposefully focused on the present moment’s stimuli. Brown and Ryan 
(2003) conceptualize awareness and attention as distinct components of mindfulness, yet also 
acknowledge the considerable overlap between the two (Brown et al., 2007).  
The MAAS was designed to assess participant levels of trait mindfulness on a day-to-day 
basis, for example, “I could be experiencing some emotion and not be conscious of it until 
sometime later” (MAAS; Brown & Ryan, 2003). Each MAAS item is answered based on a 6-
point Likert scale with scores ranging from 1-6 (6 = “Almost Never,” 5 = “Very Infrequently,” 4 
= “Somewhat Infrequently,” 3 = “Somewhat Frequently,” 2 = “Very Frequently,” or 1 = “Almost 
Always”), which can total a minimum raw score of 15 up to a maximum raw score of 90. Higher 
scores indicate greater levels of innate, dispositional mindfulness (Brown & Ryan, 2003). The 
MAAS has robust psychometric properties with Cronbach’s alphas (α; estimates of internal 
consistency or reliability) generally ranging from .80 to .90 among a national sample, samples of 
community adults, college students, and from clinical settings (Brown & Ryan, 2003; Carlson & 
Brown, 2005). Good construct validity was indicated, in that the convergent and discriminant 
validity of the theoretical concepts sufficiently define “one’s propensity to be aware of specific 
events or types of experience, whether in the internal or external world” (see Brown & Ryan, 
2003, p. 827). The MAAS also has been shown to be valid in the context of chronic illness, 
among a sample of individuals with cancer (Carlson & Brown, 2005). 
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Depression, Anxiety, and Stress Scales – Depression Subscale. Depressive symptoms 
were assessed using the Depression, Anxiety, and Stress Scales - Depression Subscale (DASS-
21; Lovibond & Lovibond 1995). The DASS-21 Depression subscale assesses depressive 
symptoms as aspects of psychological distress and negative affect including hopelessness, 
devaluing life and self, anhedonia, lack of motivation, and is distinctive from the anxiety and 
stress subscales. The DASS-21 is a 21-item, 4-point Likert-type self-report questionnaire that 
assesses for the presence, frequency, and severity of three distinct aspects of psychological 
distress – depression, anxiety, and stress (Lovibond & Lovibond 1995).  
The DASS-21 has 7 items for each subscale, and assesses participants’ symptoms as, 0 = 
“Did not apply to me at all,” 1 = “Applied to me to some degree, or some of the time,” 2 = 
“Applied to me to a considerable degree, or a good part of time,” or, 3 = “Applied to me very 
much, or most of the time” (Lovibond & Lovibond 1995). Raw subscale scores of the DASS-21 
can range from 0 to 21, with higher scores indicating greater levels of distress (Lovibond & 
Lovibond 1995). The DASS-21 exhibited good convergent and discriminant validity for 
constructs based on one’s appraisal of stressors, maladaptive coping strategies as substance 
abuse, adaptive coping with internal or external stressors by the use of emotional and 
instrumental support, and life satisfaction.  
Construct validity was assessed using a non-clinical sample of younger adults (Gloster et 
al., 2008; see also Henry & Crawford, 2005). Psychometric properties include excellent internal 
consistency, as assessed in both clinical and research settings (α = .91 to .97 for the Depression 
subscale; Gloster et al., 2008). The DASS-21 is based on a dimensional conception (Gloster et 
al., 2008) and, therefore, has no direct implications for diagnostic categorization, as postulated 
by the Diagnostic and Statistical Manual of Mental Disorders (5th ed.) (American Psychiatric 
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Association, 2013). Nevertheless, the DASS-21 is valid to distinguish depressive, anxiety, and 
stress related symptoms, and has recommended severity-related cutoff scores for each subscale. 
For the depression subscale (raw scores multiplied by 2), normal levels are 9 or less, mild 
severity ranges from 10-13, moderate from 14-20, severe from 21-27, and extremely severe 
levels are 28 or above (Lovibond & Lovibond 1995).  
Medical Outcomes Survey 36-Item Short-Form Health Survey (SF-36; version 2) – 
Physical Component: Bodily Pain Scale. The SF-36 Bodily Pain Scale (BP) consists of two 
items. The first item is scored on a 6-point response scale (i.e., none, very mild, mild, moderate, 
severe, or very severe) that assesses bodily pain as the physical intensity of the pain experienced 
in the past four weeks. The second item is scored on a 5-point Likert response scale (i.e., Not at 
all, A little bit, Moderately, Quite a bit, or Extremely) that assesses the extent to which pain has 
interfered with one’s life and daily functioning in the past four weeks. The combined score of 
these items yields an overall pain index score (Ware et al., 2007).  
The full SF-36 survey, second version, was designed to examine the health outcomes of 
general psychiatric and medical conditions in a clinical or medical setting (Ware et al., 2007; see 
also Wells et al., 1992). There are eight health domains that evaluate specific functioning and 
health-related concepts – one being bodily pain (Ware et al., 2007; items: “Intensity of bodily 
pain,” and, “Extent pain interfered with normal work”). In previous work, reliability (α) has 
ranged from .72 to .97 across the eight health domains (Ware et al., 2007), and for the BP 
subscale an α of .80 or greater has been consistently observed (Ware et al., 2007). All domains 
have shown good reliability and validity (e.g., various studies have yielded adequate content, 
concurrent, criterion, construct, and predictive evidence of validity; see Ware et al., 2007) to 
monitor health and specific health functioning (McHorney, Ware, Lu, & Sherbourne, 1994; 
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McHorney, Ware, & Raczek, 1993; Ruta, Addalla, Garratt, Coutts, & Russell, 1994; Ware et al., 
2007). Accordingly, the SF-36 may be used in a wide range of applications across various 
populations, including for those with chronic pain and disease (Ware et al., 2007).  
Alcohol Use Disorders Identification Test. Alcohol-related problems were assessed 
using the Alcohol Use Disorders Identification Test (AUDIT; Babor, Higgins-Biddle, Saunders, 
& Monteiro, 2001), a 10-item screening measure for alcohol use and problems developed by the 
World Health Organization (WHO), which includes subscales regarding one’s consumption, 
dependence symptoms, and negative consequences related to alcohol consumption (Babor et al., 
2001).  
The AUDIT has demonstrated good reliability among the general population (α > .80, 
typically), has been used with a variety of subpopulations (e.g., cross-culturally, across genders, 
and age groups) (Meneses-Gaya, Zuardi, Loureiro, & Crippa, 2009), and is considered 
appropriate to use in a variety of settings including work-related, primary care, hospital, forensic, 
military, and general settings (Babor et al., 2001). The AUDIT has excellent construct and 
internal validity, as it has been shown to differentiate 98% of respondents correctly, as either 
problematic or non-problematic drinkers, and can categorize hazardous or harmful drinking and 
alcohol dependence (Bohn, Babor, & Kranzler, 1995).  
Scores per item range from 0-4 (i.e., for frequency of drinking, typical quantity, impaired 
control over drinking, increased salience of drinking, and alcohol-related concerns) with a 
maximum score of 40, with higher scores indicative of greater risk for hazardous or harmful 
alcohol use, alcohol-related problems, and/or dependence. AUDIT cutoff scores that range from 
1-7 reflect a low risk of alcohol-related problems, and scores of 8 through 15 signify a moderate 
level of alcohol-related risk or problems. Scores of 16 to 19 represent a high level of alcohol-
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related problems, and scores of 20 or above “clearly warrant further diagnostic evaluation of 
alcohol dependence” (Babor et al., 2001, p. 20). The total AUDIT score reflects the individual’s 
level of alcohol-related risk, problems, and/or dependence and, the recommended cutoff score of 
8 or above is commonly used to indicate that an individual is likely to be a hazardous or harmful 
drinker (Babor et al., 2001).  
Drug Abuse Screening Test. Problems and consequences related to drug misuse or 
abuse were assessed using the Drug Abuse Screening Test (DAST; Bohn, Babor, & Kranzler 
1991; also, see Skinner, 1982), which is a 10-item questionnaire. Drug-related problems reported 
on the DAST refers to: 1) any use of over-the-counter or prescription medications in excess of 
the directions, 2) any use of illicit drugs and, 3) the nonmedical use of any drugs - the DAST 
does not assess for alcohol consumption (Skinner, 1982). Items endorse patterns of drug abuse 
that yield a quantitative index based on the rising levels of consequences related to drug use or 
misuse in the past 12 months, and higher scores are indicative of greater drug use related 
problems (Bohn et al., 1991; Skinner, 1982; Yudko, Lozhkina, & Fouts, 2007). Additionally, the 
cutoff score for drug abuse or dependence is typically six or greater (Yudko et al., 2007); 
however, psychometrics support the notion that a cutoff score of three or four is still highly 
indicative of drug-related problems (Carey, Carey, & Chandra, 2003).  
The DAST is validated for adults and is effective for use in research (Yudko et al., 2007) 
as well as nonclinical and clinical settings (Cocco & Carey, 1998; Skinner, 1982). Over 30 years 
ago, the internal consistency for the DAST was substantial at .92 (Skinner, 1982). Cocco and 
Carey (1998) evaluated concurrent, discriminant, and criterion-related validities, concluding that 
the DAST has sound psychometrics properties. Yudko and colleagues also conducted a 
comprehensive review of the psychometric properties of the DAST and concluded that the 
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validity, sensitivity, and specificity remain adequate (2007). Presently, the DAST continues to 
have excellent internal consistency at .88 and test retest reliability at .86 (Giguère & Potvin, 
2016).  
Pittsburgh Sleep Quality Index: Subjective Sleep Quality Component. The Pittsburgh 
Sleep Quality Index (PSQI) generates a global score based on seven components; specifically, 
subjective sleep quality rating, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, the use of sleeping medication, and the frequency of daytime dysfunction due to 
fatigue (Buysse et al., 1989). Sleep quality was assessed using the single-item PSQI Subjective 
Sleep Quality Component that assesses sleep quality during the past month and effectively 
differentiates “good” sleep from “poor” sleep (Buysse, Reynolds III, Monk, Berman, & Kupfer, 
1989). A sleep quality score can range from zero to three points. A score of zero indicates good 
overall sleep quality and a score of three indicates poor overall sleep quality.  
The global PSQI effectively distinguished poor sleepers from good sleepers, with a 
diagnostic specificity of 86.5% (Buysse et al., 1989) and sensitivity of 98.7% (Backhaus, 
Junghanns, Broocks, Riemann, & Hohagen, 2002). The internal consistency and reliability was 
found to be good at 0.83 (Buysse et al., 1989). The PSQI has good overall test-retest reliability at 
.87 (Backhaus et al., 2002). The measure also has been shown to be useful for adults in research, 
nonclinical, and clinical settings (Buysse et al., 1989). 
Multidimensional Health Profile: Health Functioning Index: Health Care Utilization 
Scale. The complete MHP is a comprehensive health instrument consisting of the psychosocial 
(MHP-P) and the physiological (MHP-H) indexes (Karoly, Ruehlman, & Lanyon, 2005). The 
MHP-H was designed to evaluate an individual’s proclivity toward health behaviors and health 
risks (Karoly et al., 2005). For the current study, the MHP-H (physiological index), Health Care 
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Utilization subscale, was used. The Health Care Utilization subscale is a self-report measure that 
consists of three items (Karoly et al., 2005). In this dataset, each item was initially gauged on a 
6-point scale (i.e., 1-6) assessing the frequency of doctor visits, overnight hospital visits, and 
emergency room treatment visits over the past year (i.e., scores were tabulated as 0 visits = 1; 1 
visit = 2; 2 visits = 3; 3 visits = 4, 4 visits = 5; 6 or more visits = 6). 
Convergent and discriminant validity evaluated the associations between health care 
utilization and related and unrelated constructs, such as previously correlated personality and 
temperament scales, and as compared to a spousal report, and found no relationships present 
(Karoly et al., 2005; Machlin, Valluzzi, Chevarley, & Thorpe, 2001). The absence of 
relationships between health indicators and health care utilization items provide evidence of 
strong discriminant validity (Karoly et al., 2005). Researchers reported good to adequate retest 
reliability coefficients for the Health Care Utilization items, with office visits at .86, 
hospitalizations at .75, and emergency room visits at .58 (Karoly et al., 2005). The MHP-H has 
been nationally normed, standardized, and validated for populations 18 years to 90 years of age. 
Thus, the Health Care Utilization subscale is valid to use in clinical or research settings to 
identify areas of clinical concern (Karoly et al., 2005).  
Statistical Analyses 
The cross-sectional data used in this study was assessed for erroneous (i.e., some external 
error is reflected) or missing data, and extreme outliers. Following the cleaning and preparation 
process, the data was determined to be sufficient for the following analyses.  
Primary Variables of Interest. The construction of the primary variables of interest was 
done using the data collected from the Survey-Monkey website, and then downloaded and 
cleaned using [SPSS]. The 15-item Mindful Attention and Awareness Scale (MAAS; the 
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independent variable) was scored on a 6-point scale. The individual item variable names used for 
construction of the MAAS total score were “MAAS1” through “MAAS15” and these 15 items 
were summed to create the MAAS total score.  
The 10-item Alcohol Use Disorders Identification Test (AUDIT; the dependent variable) 
was scored on a 5-point scale (0 to 4, except items 9 & 10, which were scored 0,2,4).   AUDIT 
item #1 specifies whether or not, and if so how often, a respondent drinks alcohol. If the 
participant responded "never," the score is 0; accordingly, participants may or may not respond 
to items 2 through 10. A logic-based syntax command was used to ensure that if a respondent 
endorsed 0 for AUDIT item #1, then items 2 through 10 were also scored 0 so that the 
respondent could be included in all AUDIT-based analyses (i.e., total score and subscale scores), 
the AUDIT total score. Thus, allowing for a more accurate representation of alcohol-related 
problems among the sample. The individual item variable names used for construction of the 
total score were “AUDIT1a” through “AUDIT10a” and these 10 items were summed to create 
the total score.  
The Depression Anxiety Stress Scales - 21 (DASS-21 - Depressive Symptoms subscale; 
one of two mediator variables) (7 items), was scored on a 4-point scale (1-4). Although this 
measure was originally developed to be scored as 0,1,2,3, both are 4-point scales and the 
situation described in the context of the AUDIT (regarding the incomplete data scenario) was not 
present. The 7 items were summed to create the total subscale score. The other mediator variable, 
bodily pain was measured by summing 2 items and a total score was created. 
Covariates included the 10-item Drug Abuse Screening Test (DAST) was scored 1 = Yes 
and 2 = No (2-point scale). DAST items 1-10 were scored 0 = No and 1 = Yes (2-point scale). 
Also, consistent with the AUDIT, regarding the incomplete data scenario, a logic-based syntax 
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command was created to ensure that if a respondent endorsed 0 or “No” for DAST item #1 
(“Have you used drugs other than those required for medical reasons?”), then items 2-10 were 
also scored 0 so that the respondent could be included in all DAST-based analyses (i.e., total 
score). Thus, allowing for a more accurate representation of illicit drug use/problems among the 
sample. These 10 items were summed to create the total score.  
Likewise, sleep quality was measured using a single item from the Pittsburgh Sleep 
Quality Index which was scored 1,2,3,4. Health care utilization was measured by summing 3 
items taken from a larger scale.  Importantly, these 3 items generally assess the number of visits 
to a physician’s office, the hospital, and the emergency room. The scoring is intended to 
generally correspond with the number of visits. This 3-item measure based on a 5-point scale 
(i.e., 1,2,3,4,5), with scoring, in effect: 1 = 0 visits; 2 = 1 visit; 3 = 2 visits, 4 = 3 visits; 5 = 4 or 
more visits.   
Bivariate Analyses. Pearson’s product-moment correlation coefficient (r) was used to 
evaluate the zero-order associations among the study variables. Multicollinearity was evaluated 
based on r ≥ .80 (Field, 2013) and was not detected. 
Mediation. Mediation analysis (see Figure 1), consistent with Hayes (2013; see also 
Preacher & Hayes, 2008a; 2008b), was conducted. Specifically, a parallel multiple mediation 
model with both mediator variables (MVs) included simultaneously (depressive symptoms and 
bodily pain). Parallel mediation, as opposed to serial mediation, more accurately represented the 
variables. The markers for both depression and pain cannot be removed from the 
multidimensional, simultaneous experience produced, and in turn, cannot be held in isolation of 
each other when evaluated statistically. In reality, the experience of comorbid chronic pain and 
depressive symptoms are never without the influence of the other, which poses a methodological 
 52 
 
challenge. By simulating the actual variables’ relationship - including them simultaneously - the 
best statistical reenactment was utilized.  
Mediational models may produce a variety of results (see Figure 1), including a total 
effect (i.e., c, the association of the IV with the DV, without accounting for any MVs), a direct 
effect (i.e., cʹ, the association of the IV with the DV, after accounting for the MVs), a total 
indirect effect (i.e., ab, the association of the IV with the DV, operating through the MVs), and a 
specific indirect effect (e.g., a1b1, the association of the IV with the DV through a particular 
MV). The presence of a significant indirect effect(s) in the context of the pattern of significance 
among the total effect and the direct effect allows description of the indirect mechanism of 
association to be described as a mediated effect (ab and/or a1b1, etc. are significant, and c and/or 
cʹ are significant) or an indirect only effect (ab and/or a1b1, etc. are significant, and c and cʹ are 
non-significant) (see Hayes, 2013).  
Advantages of the statistical mediation methods developed by Hayes and colleagues (e.g., 
Bauer, Preacher, & Gil, 2006; Hayes, 2009; 2013; Preacher & Hayes, 2008a; 2008b) over the 
methods developed by Baron and Kenny (1986) include the facts that indirect effects can be 
tested without requiring: (1) a direct effect between the IV and the DV, thereby decreasing Type 
II error, and, (2) the assumption of normally distributed data in the context of assessing for 
indirect effects. Regarding the latter, bootstrap resampling (Hayes, 2013), a technique that 
produces bias-corrected confidence intervals, was utilized to evaluate the indirect effect of the IV 
on the DV, operating through potential MVs (Hayes, 2013; Preacher & Hayes, 2008a; 2008b). 
Hayes (2013) recommends using a minimum of 10,000 resamples, as a greater collection of 
simulations of the empirical distributions of the data increases the likelihood of observing the 
true standard errors, confidence intervals, and significance values. Also, bootstrap resampling 
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bolsters statistical power and is more sensitive in detecting effects, particularly in smaller sample 
sizes (Hayes, 2013).   
Power analysis.   It is common practice to have at least a .80 probability to reject the 
null; without appropriate power, sample sizes may be too small to detect effect sizes, or large 
sample sizes may be wasteful of valuable resources while only providing small, if any, effect or 
benefit to the participants (Cohen, 1988). While the data included in this study was collected as 
part of a larger study, and the final sample size is a function thereof, a general rule of thumb for 
regression-based analyses is 10-20 participants per predictor variable (Field, 2013). Including the 
IV, MVs, and covariates (i.e., poor sleep quality, drug-related problems, and health care 
utilization), there were 7 predictor variables in this secondary analysis; as such, our study needed 
70-140 participants to detect small effect sizes.  
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CHAPTER 3 
RESULTS 
Survey data were analyzed using SPSS. Data were cleaned, screened for outliers, and 
assessed for missing data after completion of the survey. Results of the study are organized as 
follows: 1) demographic descriptive statistics; 2) bivariate results - Pearson’s product-moment 
correlation coefficients, 3) multivariable associations - statistical mediation analysis, and; 4) 
exploratory analyses and results.  
Demographic Descriptive Statistics 
The sample (n = 287) self-reported as 91.64% White/Caucasian, 2.78% as Black/African-
American, 1.04% as Asian, 2.43% as Multiracial, and 2.11% as “do not know” or missing. In 
addition, 4.18% of White/Caucasians self-reported as being of Hispanic or Latino origin. 
Participants were almost entirely female (97.56%), and ages ranged from 21.19 to 78.13 years 
old (M = 51.05; SD = 11.63). The sample appears to be similar to the target population (see 
Castro‐Sánchez et al., 2012; also, Lawrence et al., 2008). See Table 2 below for more 
demographic information.  
Table 2  
Demographic Information (N = 287) 
 
 
Variable – Subvariables 
 
Sample 
 
Percent 
Sex   
 Female n = 280 97.56% 
 Male n = 7 2.44% 
 Missing n = 0 - 
Age, in years n = 287 M = 51.05, SD = 11.63 
 Missing n = 0 - 
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Variable – Subvariables Sample Percent 
       White/Caucasian n = 263 91.64% 
Black/African-American n = 8 2.78% 
Asian n = 3 1.04% 
Multiracial n = 7 2.43% 
Missing or Don’t Know n = 6 2.11% 
Of Hispanic or Latino Origin    
       Hispanic or Latino  n = 12 4.18% 
Not Hispanic or Latino  n = 273 95.12% 
Missing n = 2 .70% % 
Years of Education   
 GED or HS Diploma n = 87 30.31% 
 Associate’s Degree n = 55 19.16% 
       Bachelor's Degree n = 71 24.73% 
Master's Degree n = 41 14.28% 
Doctorate or Postdoctoral Degree n = 6 2.09% 
Missing n = 27 9.43% 
Sexual Orientation    
       Homosexual n = 13 4.52% 
Heterosexual n = 248 86.41% 
Bisexual n = 14 4.87% 
Undetermined n = 2 0.69% 
Refuse to answer n = 3 1.04% 
Missing n = 7 2.47% 
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Variable – Subvariables Sample Percent 
       Single, never married n = 41 14.29% 
Married n = 169 58.89% 
Separated n = 8 2.79% 
Divorced n = 54 18.82% 
Widowed n = 8 2.79% 
Missing n = 7 2.42% 
 
Bivariate Analyses  
In order to examine zero-order associations between study variables and to test 
Hypothesis 1 among people with fibromyalgia, Pearson’s product-moment correlation 
coefficients were computed (See Table 3 below for bivariate correlation results). Hypothesis 1 
was partially supported. Bivariate correlation coefficients demonstrated that mindfulness was 
significantly and negatively associated with depressive symptoms (r = -.41, p < .001) and 
alcohol-related problems (r = -.15, p < .05). Correlation results also only partially statistically 
supported the first hypothesis, demonstrating that bodily pain and depressive symptoms 
significantly and positively related to poor subjective sleep quality (r = .35 and .24, respectively, 
both, p < .001). Bodily pain and depressive symptoms also were significantly and positively 
related to each other (r = .22, p < .001). However, only bodily pain was significantly and 
positively related to health care utilization (r = .23, p < .001) and negatively related to drug-
related problems (r = -.16, p < .01).  
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Table 3  
Bivariate Correlations for Key Study Variables (N = 287) 
Measures 1. 2. 3. 4. 5. 6. 7. 
1. Mindfulness   --       
2. Depressive Symptoms -.41** --      
3. Bodily Pain  -.05 .22** --     
4. Alcohol-Related Problems  -.15* .05 .03 --    
5. Drug-Related Problems  -.08  .04 -.16** .19** --   
6. Health Care Utilization  -.04 .11 .23**  .02 -.05 --  
7. Poor Sleep Quality  -.17** .24** .35** -.02 -.03 .20** -- 
 
*  
**. Correlation is significant at the 0.01 level (2-tailed) 
*. Correlation is significant at the 0.05 level (2-tailed)  
p < .10; ns = non-significant 
 
Multivariable Associations 
Table 4 (see below) includes results relevant to Hypothesis 2 and the statistical mediation 
model illustrated in Figure 1; for example, unstandardized regression coefficients for each 
pathway segment (a1, a2, b1, b2, c, c') and the effects for each indirect pathway as a whole (ab, 
a1b1, a2b2). Only statistically significant results (i.e., p < .05; 95CI did not cross zero) will be 
described in detail (for statistically non-significant results, see Table 4). Hypothesis 2 was 
largely not supported. See 
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Table 4  
 
Direct and Indirect Associations between Mindfulness and Each Dependent Variable with 
Control Variables (N = 287) 
 
§Total Effect Model R2 = .0576** 
 
‡Overall Effect Model R2 = .0630** 
  coefficient p value 
 
a1 
 
-.1484 
 
< .0001**** 
a2 -.0001          .9816 
b1 -.0108  .6611 
b2 .0995 .2152 
C -.0207 .0165* 
c' -.0223 .0175*  Effect 95CI 
Ab .0016 -.0077 .0096 
a1b1 .0016 -.0075 .0095 
a2b2 .0000 -.0019 .0016 
 
Covariates: Health Care Utilization, Poor Sleep Quality, and Drug-Related Problems 
 
a1  = basic association of Mindfulness with Depressive Symptoms 
a2  = basic association of Mindfulness with Bodily Pain 
b1  = basic association of Depressive Symptoms with Alcohol-Related Problems 
b2  = basic association of Bodily Pain with Alcohol-Related Problems 
 
ab  = total indirect effect 
a1b1  = specific indirect effect of Mindfulness on Alcohol-Related Problems through Depressive Symptoms 
a2b2  = specific indirect effect of Mindfulness on Alcohol-Related Problems through Bodily Pain 
 
c  = total effect of Mindfulness on Alcohol-Related Problems, without accounting for any Mediator Variables 
c'  = direct effect of Mindfulness on Alcohol-Related Problems, after accounting for all Mediator Variables 
 
95CI = Bias-corrected 95% Confidence Interval 
* p < .05; ** p < .01; *** p < .001; **** p < .0001; † < .10; ns = non-significant 
§ = without accounting for any Mediator Variables 
‡ = after accounting for all Mediator Variables 
 
For multivariable associations, while controlling for poor sleep quality, health care 
utilization, and drug-related problems, it was hypothesized that, among people with 
fibromyalgia, mindfulness would have a direct, statistically negative relationship with alcohol-
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related problems, bodily pain, and depressive symptoms (Hypothesis 2a). In the context of 
alcohol-related problems, the total (c =.-.02) and direct (c' = -.02) effects of mindfulness were 
statistically significant, such that with or without the mediator variables included in the analysis, 
higher levels of mindfulness were associated with fewer alcohol-related problems. For 
depressive symptoms, the association was statistically significant (a1 = -.15), such that higher 
levels of mindfulness were associated with lower levels of depressive symptoms. For bodily 
pain, the association was non-significant (a2 = -.00). Similarly, Hypothesis 2b stated: bodily pain 
and depressive symptoms will have a direct, statistically positive relationship with alcohol-
related problems. For depressive symptoms (b1 = -.01) and bodily pain (b2 = .10), the association 
with alcohol-related problems was statistically non-significant. 
Finally, Hypothesis 2c stated: the association of mindfulness with alcohol-related 
problems will be mediated by bodily pain and depressive symptoms. That is, higher levels of 
mindfulness will be associated with lower levels of both bodily pain and depressive symptoms 
that, in turn, will be associated with less alcohol-related problems. As outlined in Table 4, the 
association of mindfulness with alcohol-related problems among people with fibromyalgia was 
not observed to operate through depressive symptoms and bodily pain as mediators. That is, the 
total indirect effect (ab = .00), the specific indirect effect through depressive symptoms (a1b1 = 
.00), and the specific indirect effect through bodily pain (a2b2 = .00) were each statistically non-
significant.  
In sum, Hypothesis 1 received partial support and Hypothesis 2 received very little 
support. That is, at the bivariate level of analysis, there were some associations among the 
variables of interest supporting the notion that mindfulness may be associated with alcohol-
related problems among people with fibromyalgia and that depressive symptoms and bodily pain 
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may be mechanisms of this association. However, at the multivariable level of analysis, the more 
complex associations hypothesized were not supported. Upon reflection, it may be that the 
hypothesized model was over-controlled. As such, an additional exploratory analysis was 
conducted, excluding the originally hypothesized covariates of poor sleep quality, health care 
utilization, and drug related problems. 
Exploratory Analysis. Table 5 includes results relevant to this exploratory analysis and 
the statistical mediation model illustrated in Figure 1; for example, unstandardized regression 
coefficients for each pathway segment (a1, a2, b1, b2, c, c') and the effects for each indirect 
pathway as a whole (ab, a1b1, a2b2). Only statistically significant results (i.e., p < .05; 95CI did 
not cross zero) will be described in detail (for statistically non-significant results, see Table 4).  
Table 5 
Direct and Indirect Associations between Mindfulness and Each Dependent Variable without 
Control Variables (N = 287) 
 
§Total Effect Model R2 = .0225* 
 
‡Overall Effect Model R2 = .0237† 
  coefficient p value 
 
a1 
 
-.1608 
 
   < .0001**** 
a2  -.0059 .3967 
b1  -.0098 .6924 
b2  .0367 .6243 
c -.0219 .0109 
c' -.0233 .0141  Effect 95CI 
ab  .0014 -.0087 .0100 
a1b1  .0016 -.0081 .0102 
a2b2 -.0002 -.0031 .0005 
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Table 5 Continued 
 
Covariates: None 
 
a1  = basic association of Mindfulness with Depressive Symptoms 
a2  = basic association of Mindfulness with Bodily Pain 
b1  = basic association of Depressive Symptoms with Alcohol-Related Problems 
b2  = basic association of Bodily Pain with Alcohol-Related Problems 
 
ab  = total indirect effect 
a1b1  = specific indirect effect of Mindfulness on Alcohol-Related Problems through Depressive Symptoms 
a2b2  = specific indirect effect of Mindfulness on Alcohol-Related Problems through Bodily Pain 
 
c  = total effect of Mindfulness on Alcohol-Related Problems, without accounting for any Mediator Variables 
c'  = direct effect of Mindfulness on Alcohol-Related Problems, after accounting for all Mediator Variables 
 
95CI = Bias-corrected 95% Confidence Interval 
* p < .05; ** p < .01; *** p < .001; **** p < .0001; † < .10; ns = non-significant 
§ = without accounting for any Mediator Variables 
‡ = after accounting for all Mediator Variables 
 
The exploratory analysis excluded the covariates of poor sleep quality, health care 
utilization, and drug-related problems and, again, the association of mindfulness with alcohol-
related problems among individuals with fibromyalgia was observed to be direct and negative, 
but was not observed to operate through depressive symptoms and bodily pain as mediators. That 
is, the total indirect effect (ab = .00), the specific indirect effect through depressive symptoms 
(a1b1 = .00), and the specific indirect effect through bodily pain (a2b2 = -.00) were each 
statistically non-significant.  
In sum, both mediation-based models were statistically non-significant; although there 
appears to be a negative direct effect between mindfulness and alcohol-related problems, 
mindfulness does not appear to have an indirect effect on alcohol-related problems via bodily 
pain and depressive symptoms in this sample of people with self-identified fibromyalgia. 
Relevant findings are discussed below, using a list of the hypotheses as a framework for 
discussion. Where applicable, broader implications of the findings, including potential methods 
to improve well-being for individuals, particularly those who have fibromyalgia, are discussed. 
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CHAPTER 4 
DISCUSSION 
The purpose of the present study was to investigate the relationship between mindfulness, 
pain and depressive symptoms, and alcohol-related problems, in a sample of those who reported 
the onset of fibromyalgia symptoms or a diagnosis of fibromyalgia. It was observed that: 1) 
mindfulness was associated with alcohol-related problems, and; 2) that this relationship was not 
mediated by pain or depressive symptoms.  The broad hypotheses regarding mindfulness being 
negatively associated with alcohol-related problems among people with fibromyalgia and that 
pain and depressive symptoms would mediate this relationship, received partial support. Our 
primary findings, although consistent with relevant research, largely only supported the 
relationship between mindfulness and alcohol-related problems (e.g., Bien, 2009; Garland et al., 
2012; Grossman et al., 2004; Grossman et al., 2007; Kaplan et al., 1993; Hayes et al., 2012; 
Miller & Rollnick, 2013; Parra-Delgado & Latorre-Postigo, 2013; Pearson et al., 2014). 
Nevertheless, the findings may have implications for the treatment of alcohol use problems and 
managing related consequences. 
Over the past decade, the mindfulness construct has received greater recognition in both 
the clinical and empirical domains. Yet, debate over the precise operationalization of 
mindfulness continues. The generally accepted conceptualization of mindfulness involves 
intentionally directing attention toward the present moment and adopting a nonjudgmental and 
nonreactive mindset, intent, and attitude (Bishop et al., 2004; Brown & Ryan, 2003; Grossman, 
2008; 2011; Kabat-Zinn, 2013; Shapiro et al., 2006). Empirical literature suggests that 
mindfulness relates to decreased levels of depressive symptoms (Segal et al., 2013) and 
subjective experiences of pain (Kabat-Zinn, 1982); whereas, both depression and pain contribute 
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risk for increased alcohol-related problems (Askay et al., 2009). Examining pain and depressive 
symptoms, among those with fibromyalgia, provided a means of focusing on a relatively discrete 
aspect of well-being and how mindfulness may have an indirect relationship with alcohol-related 
problems.  Yet, understanding of the potential underlying factors affecting the relationship 
between mindfulness and outcomes, such as alcohol-related problems is limited. As such, 
bivariate correlations and parallel mediation models were examined to better understand the 
association.  
Despite the continued promise of mindfulness techniques to increase attentional control 
and improve well-being, some fundamental questions regarding the underlying effects of 
mindfulness remain (Grossman, 2011). Among those with fibromyalgia, specific mechanisms by 
which mindfulness might beneficially affect one’s physical or psychological well-being have 
been relatively overlooked in the psychological literature (Parra-Delgado & Latorre-Postigo, 
2013; Wolfe et al., 2013). Many studies evaluated the effect of mindfulness on chronic pain or 
depressive symptoms (e.g., Barnhofer & Crane, 2009; Kabat-Zinn, 1994; 2007; Segal et al., 
2013). Limited studies evaluated these variables also to the potential relation with alcohol-related 
problems (e.g., Bien, 2009; Garland et al., 2012; Pearson et al., 2014), and a scarce number of 
studies evaluated the key study variables among those with fibromyalgia (Parra-Delgado & 
Latorre-Postigo, 2013).  
Mindfulness associations. At the multivariable level of analysis, after controlling for 
poor sleep quality, health care utilization, and drug-related problems, mindfulness did have a 
direct, statistically negative relationship with alcohol-related problems among people with 
fibromyalgia, and depressive symptoms; however, not with bodily pain (Hypothesis 2a).   These 
particular findings support previous research indicating that higher levels of mindfulness can be 
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a valuable resource for decreasing both alcohol-related problems (Bien, 2015) and depressive 
symptoms (Hofmann et al., 2010; Segal et al., 2013).  
The disabilities that accompany fibromyalgia often encumber an individual’s sense of 
well-being and may deplete adaptive coping efforts (Hayes et al., 2012). Previous research has 
shown that many use alcohol to self-medicate as a coping mechanism (Singh, 2012). Awareness 
of and attention to alcohol-related problems may help individuals determine what changes to 
make to their alcohol use (Miller & Rollnick, 2013). Increased mindfulness may contribute to a 
more meaningful view of chronic symptoms by cognitive reframing of symptoms and functional 
limitations through a more objective, nonjudgmental mindset (Segal et al., 2013; Sephton et al., 
2007; Williams et al., 2007). Thus, mindfulness was theorized to decrease alcohol-related 
problems by functioning as an effective coping strategy (Fernandez et al., 2014; Song et al., 
2014) and augmenting self-awareness and attention to alcohol use patterns and consequences 
(Pearson et al., 2014).  
Considering possible other mechanisms, there are a number of reasons that higher levels 
of mindfulness may be associated with less alcohol-related problems. One proposed mechanism 
that was tested in the current study is chronic pain. In previous research, greater mindfulness is 
associated with lessened chronic pain symptoms (Kabat-Zinn, 1994), which in turn leads to less 
alcohol-related problems, perhaps by reducing self-medication of pain symptoms (Singh, 2012). 
While this model was statistically non-significant in the current study, there are other pathways 
by which mindfulness and alcohol-related problems may be associated. For example, pain was 
correlated with drug-related problems (DAST), and depressive symptoms (DASS) at the 
bivariate level.  
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For depressive symptoms among people with fibromyalgia, we observed higher levels of 
mindfulness to be associated with lower levels of depressive symptoms, at both the bivariate and 
multivariable levels of analysis. Interventions incorporating mindfulness techniques in 
therapeutic settings have been shown to be effective across a wide variety of populations and 
health issues, including both psychological and medical disorders (Grossman et al., 2004; Hayes 
et al., 2012; Kabat-Zinn, 1994).  Mindfulness also has been used in the treatment of depressive 
symptoms as an ability to discern between cognitive events and the totality of the individual. 
Mindfulness thus involves a disidentification from the activity of the mind (Segal et al., 2013); 
by becoming aware of sensations, images, feelings and thoughts the mindful individual identifies 
that these phenomena are merely passing events (Hayes et al., 2012). As previously observed, 
mindfulness may aid in the management of depressive symptoms, specifically, mindfulness-
based interventions have been shown to have immense therapeutic potential for the treatment of 
depression (Segal et al., 2013). 
Relation of bodily pain and depressive symptoms with alcohol-related problems.  
This study did not find a statistical association with alcohol-related problems for either bodily 
pain or depressive symptoms (Hypothesis 2b). However, other studies have shown that these 
variables tend to be associated with each other (Singh, 2012). Perhaps, alcohol-related problems 
were not a sufficiently large concern for the sample included in this study. Scores or 8 or above 
on the AUDIT suggest a likelihood for hazardous or harmful drinking (Babor et al., 2001). In 
this sample, the average AUDIT total score (M = 1.43; SD = 2.01) was less than 8.  Thus, if 
individuals do not report consequences from drinking patterns, as conceptualized from the 
AUDIT measure, deleterious effects are less likely to be detected. Perhaps among those with 
limited ability to engage in daily activities, alcohol-related problems may be displayed in other 
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ways than measured by the AUDIT. Nevertheless, it is possible that alcohol-related problems 
could contribute to the development of depressive symptoms; however, this study’s findings did 
not evaluate such associations.  
Table 6 
 
Means and Standard Deviations for Key Variables 
Measures Number of Items Mean Standard Deviation  
MAAS 15 55.23 13.78 
DASS: DEP 7 15.03 5.39 
SF-36: BP 2 8.38 1.62 
AUDIT-10 10 1.43 2.01 
 
Note: MAAS scores are in raw form; for interpretation divide mean by the total number of items, 15; possible range 
for raw scores is 15-90. 
Note: AUDIT scores < 8 are considered alcohol-related problems (Babor et al., 2001); possible range equals 0-40.   
Note: DASS: DEP scores possible range is 0-21. 
Note: SF-36: BP scores possible range is 2-11.  
  
Mindfulness, bodily pain, and depressive symptoms, in the context of alcohol-related 
problems. The association of mindfulness with alcohol-related problems was not mediated by 
bodily pain and depressive symptoms (Hypothesis 2c). While there was a direct relationship 
between mindfulness and alcohol-related problems, neither the combined effect of bodily pain 
and depressive symptoms was statistically significant nor the individual specific indirect effects 
through bodily pain or depressive symptoms.  Several factors may explain why the current 
results were not consistent with previous research that supports the relationships between and 
among mindfulness, bodily pain, depressive symptoms, and alcohol-related problems. Indeed, 
the present results stand in contrast to most of the current literature on mindfulness that suggests 
that mindfulness is related to many cognitive, emotional, and physical benefits (Baer et al., 2012; 
Garland & Black, 2014; Kabat-Zinn, 2013; and Segal et al., 2013). Thus, the results of this, a 
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single study should not be relied upon as compelling evidence to the contrary. The notable 
divergence of the current findings could be accounted for by a variety of explanations.  
For trait mindfulness studies using the MAAS, such as ours, significant relationships 
between mindfulness and related concepts may arise from unmeasured other variables.  
According to Shapiro and colleagues (2006), self-regulation may be the key aspect to how 
mindfulness improves health.  Indeed, an ongoing debate continues in the literature, as to 
whether the MAAS scale effectively detects all aspects, or the most important aspects of 
mindfulness (Grossman, 2011), even though the MAAS was intended to assess the most 
scientifically measurable factors of mindfulness [i.e., attention and awareness; (Park, Reilly-
Spong, & Gross, 2013).  
In fact, attempts to measure mindfulness vary considerably across different self-report 
measures of mindfulness. Some researchers have described the MAAS measure as lacking 
evidence to report robust convergent, construct, and content validities, and that there is lacking 
evidence that self-reported mindfulness levels correspond to actual mindful behavior (Grossman, 
2008; 2011). This debate goes on to include certain therapies related to the mindfulness 
construct. Grossman (2011) stated that self-report measures of mindfulness may “serve to 
denature, distort, and banalize the meaning of mindful awareness in psychological research and 
may adversely affect further development of mindfulness-based interventions” (p. 1034). These 
issues should be considered in future developments in the self-report assessment of mindfulness 
and likely will help develop more confidence in mindfulness-based research findings – whether 
salutary or deleterious.  
A multi-dimensional measurement of mindfulness should be incorporated in future 
studies. For example, the Kentucky Inventory of Mindfulness Skills (KIMS) consists of four 
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subscales that evaluate body sensations, thoughts, emotions, and external stimulus (Baer, Smith, 
& Allen, 2004). Likewise, the Freiburg Mindfulness Inventory (FMI), the Cognitive and 
Affective Mindfulness Scale-Revised (CAMS-R), the Five Facet Mindfulness Questionnaire 
(FFMQ), the Toronto Mindfulness Scale (TMS), the Mindfulness/Mindlessness Scale (MMS), 
the Philadelphia Mindfulness Scale (PHLMS), and the Southampton Mindfulness Questionnaire 
(SMQ) are reported to have overall good validity, and not dissimilar to some MAAS validity 
findings (Park et al., 2013). Nevertheless, there is a “great need to establish … validity… 
[across] diverse populations, and clinical populations with acute and chronic illnesses” (Park et 
al., 2013; p. 11). The inclusion of various diversity intersections, across visible and latent 
domains, is needed to better understand these relationships’ underlying mechanisms.  
Another possible explanation as to why the present findings are contrary to some of the 
currently accepted research is that mindfulness may be a learned skill that must be induced by 
habitual mental practice (see Christopher et al., 2009; and Kabat-Zinn, 2013). It is possible that 
the methods utilized in the previous studies actually elicited reportable changes in levels of 
mindfulness, whereas, our study is measuring differences in dispositional/trait mindfulness.  
Nevertheless, individuals were able to report on trait mindfulness levels in the absence of any 
mindfulness-based practice. There is a possibility that the sampling in this particular study has 
potential effects of mindfulness that were not discovered, but may have been if a more 
comprehensive measure of mindfulness (e.g., Five Facet Mindfulness Questionnaire, see Baer, 
Smith, Hopkins, Krietemeyer, & Toney, 2006) was utilized (i.e., Type II error), which should 
prompt further investigation.  Baer et al. (2006) suggested a five-factor structure of mindfulness 
characterized by nonreactivity, observing, acting with awareness, describing, and nonjudging.  
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Moreover, consideration should be given to the notion that therapies that include 
mindfulness techniques may in essence be functioning differently than trait mindfulness.  
Simply, the concept of trait mindfulness and mindfulness-based interventions are not as related 
as previously theorized, suggesting that the current conceptualizations of mindfulness and its 
expected effects need revision. Mindfulness-based approaches are increasingly utilized to treat 
various health conditions.  Consistently throughout literature, mindfulness-based approaches 
have been shown to be effective to help improve health.  Trait mindfulness also has been shown 
to have strong associations with many health variables.  Yet, it is unclear if results from 
mindfulness-based intervention research studies can be compared to results from studies that 
evaluate trait or state mindfulness.  Significant differences exist across different mindfulness 
constructs. Some describe mindfulness as a mental state or an innate dispositional trait (Brown & 
Ryan, 2003). For example, the mindfulness-based intervention research studies, evaluated in this 
present study, did not report evaluating trait mindfulness as a qualifier to participate in 
mindfulness-based treatments. Rather, individuals used the intervention as a method to train their 
attention and awareness, and, in order to observe the present reality, from moment to moment, 
objectively (Kabat-Zinn, 2013). So far, no consensus has been reached as to how mindfulness 
should be defined, conceptualized, and operationalized. Nevertheless, there is overall agreement 
that mindfulness involves attention and awareness, in the present moment, which is similar to 
Brown and Ryan’s (2003) mindfulness construct and scale. Indeed, more research is needed to 
clarify the relationship between trait mindfulness and mindfulness skills.   
Limitations. The current findings must be considered within the context of important 
limitations. Measurement issues, such as assessments with few items, one-dimensional factor 
structure of a measure (e.g., MAAS - mindfulness with present-centered attention/awareness as 
 70 
 
main feature), and the usage of self-report measures (e.g., social desirability, the personal 
motivation why somebody engages in a study needs to be considered) limited the power and 
accuracy of the results. Also, as with all correlational, cross-sectional studies, for example, 
assumptions cannot be made regarding the causal order of the variables examined. The variables 
chosen and the ordering and direction of the variables entered in the mediation model were based 
on theory and previous empirical work. However, more research, particularly that which is 
longitudinal, and/or intervention-based, is needed to further examine the causal associations 
otherwise hypothesized in this study.  
Measurement issues may have affected the outcome of the study and the statistical 
findings. For instance, the reliability estimate for the Health Care Utilization scale showed a low 
alpha (see Table 5). This suggests that the unbiased estimate of the generalizability for the Health 
Care Utilization scale is minimal reliability.  Moreover, the use of a one-item measure for a 
control variable (i.e., Sleep Quality), a two-item assessment (i.e., Bodily Pain) for one of the 
mediator variables, and a three-item assessment for a covariate (e.g., Health Care Utilization) 
was less than ideal. Measures that have few items tend to tap into only one dimension, or part of 
one aspect of a concept. In addition, single item measures cannot easily detect the degree and 
scope of a construct. Indeed, the use of multi-item scales often improves reliability by better 
testing full continua and breadth of constructs (McCoach, Gable, & Madura, 2013). For future 
research, the use of more sophisticated measures for analyses likely would enrich the dataset and 
allow for better control of measurement error by multi-item means leveling out when individual 
item scores are summed to obtain total scores (Hayes, 2013).  
Arguably, another problem with using the Bodily Pain subscale (SF-36) was that it 
measures for ‘bodily’ pain and not levels of ‘chronic’ pain. While the measure was validated 
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with some individuals who had chronic pain (Ware et al., 2007), the instrument could likely be 
measuring another variable that is similar to, but not, ‘chronic pain’ per se. There may be distinct 
differences in how bodily pain and chronic pain are measured. Accordingly, other measures that 
assess chronic pain ought to be considered for future research. For instance, there are 
inconsistent reports regarding whether the DAST predicts aberrant drug-related behaviors among 
individuals who experience chronic pain symptoms and are being treated with pain medication 
(Passik & Kirsch, 2008).  Meaning, that it is unclear if the specific drug-related problems 
mentioned in the DAST measure are relevant among individuals with fibromyalgia, who are 
being treated with opioids for chronic pain.   
Each measure used in this study had undergone testing for reliability and validity. In spite 
of efforts to produce strong, valid, and reliable measures, self-report measures are still 
susceptible to errors since scale values are merely an arbitrary assignation of a quantity of a 
latent variable, allowing researchers to operationalize, but which may lead to measurement errors 
(McCoach et al., 2013).  Alternatives to self-report are phenomenological, neuropsychological, 
biofeedback, and behavioral tools.  Additionally, even when participants answer honestly, some 
may lack the introspective ability to provide an accurate response to an item (Hahn, Judd, Hirsh, 
& Blair, 2014).  
Future Directions 
Further research is needed to more fully evaluate the relationship of mindfulness to 
different modes of pain and depression-related variables in the context of alcohol-related 
problems among those with fibromyalgia. Future research should evaluate the different types of 
chronic pain, and how chronic pain is experienced among various populations. Studies should 
also evaluate this across different diversity intersections (e.g., age, location, ethnicity, race, 
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gender, religious beliefs, ability levels, health status, etc.). The use of different measures (i.e., of 
mindfulness, chronic pain, depression, alcohol-related problems, and the control variables) 
should likely also be evaluated, perhaps using other/additional statistical techniques. In 
particular, the association between mindfulness and alcohol-related problems among those with 
fibromyalgia should be further examined. Future research might explore other potential 
mediators of these relationships (e.g., engaging psychotherapy, etc.) that may provide additional 
insight into the relationship between mindfulness and alcohol-related problems. 
Conclusions 
 In the current study, individuals with fibromyalgia self-reported their experiences with 
pain, depressive symptoms, and alcohol-related problems, as well as levels of trait mindfulness. 
Results indicated no indirect effect of mindfulness, particularly its components of attention and 
awareness, on alcohol-related problems through bodily pain and depressive symptoms. However, 
there was a direct negative relationship between mindfulness and alcohol-related problems. 
Overall, the results did not support most hypotheses. More research is needed to address the 
current limitations and expand research and understanding of the mechanisms of the association 
between mindfulness and alcohol-related problems among people with fibromyalgia.  
Mindfulness techniques are increasing as one of the primary foci in multiple 
psychological therapies (e.g., MBSR, DBT, MBCT, ACT). There have been numerous studies 
documenting the effectiveness of mindfulness-based interventions, which aim to increase 
mindfulness-based abilities or skills. There is a lack of clarity regarding the association of trait 
mindfulness, mindfulness practices, and health variables among individuals with fibromyalgia. 
Examining the relationships between trait mindfulness and health variables is important for 
better understanding the effects of having a higher level of dispositional mindfulness in everyday 
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life. A better conceptualization of these variables may facilitate ways in which individuals with 
fibromyalgia may be better supported throughout their treatment and how one’s level of trait 
mindfulness is associated with other important areas of life. 
  
 74 
 
REFERENCES 
American Pain Society (2005). Guideline for the management of fibromyalgia syndrome pain in 
adults and children. Glenview, IN: Author.  
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders 
(5th ed.). Arlington, VA: American Psychiatric Publishing. doi: 
10.1176/appi.books.9780890425596 
Askay, S. W., Bombardier, C. H., & Patterson, D. R. (2009). Effect of acute and chronic alcohol 
abuse on pain management in a trauma center. Expert Review Neurotherapeutics, 9(2), 
271–277. doi:10.1586/14737175.9.2.271 
Baer, R. A., Smith, G. T., & Allen, K. B. (2004). Assessment of mindfulness by self-report: The 
Kentucky Inventory of Mindfulness Skills. Assessment, 11(3), 191–206. doi: 
10.1177/1073191104268029 
Baer, R. A., Smith, G. T., Hopkins, J., Krietemeyer, J., & Toney, L. (2006). Using selfreport 
assessment methods to explore facets of mindfulness. Assessment, 13, 27- 45. doi: 
10.1177/1073191105283504 
Baer, R. A., Lykins, E. B., & Peters, J. R. (2012). Mindfulness and self-compassion as predictors 
of psychological wellbeing in long-term meditators and matched nonmeditators. The 
Journal of Positive Psychology, 7(3), 230-238. doi:10.1080/17439760.2012.674548 
Baer, R. A. (2011). Measuring mindfulness. Contemporary Buddhism: An Interdisciplinary 
Journal, 12(1), 241-261. doi:10.1080/14639947.2011.564842 
Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). AUDIT The 
Alcohol Use Disorders Identification Test: Guidelines for use in primary care (2nd ed.). 
Geneva, Switzerland: World Health Organization.  
 75 
 
Backhaus, J., Junghanns, K., Broocks, A., Riemann, D., & Hohagen, F. (2002). Test-retest 
reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. 
Journal of Psychosomatic Research, 53(3), 737-740. doi:10.1016/S0022-3999(02)00330-
6 
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003). Depression and pain 
comorbidity: A literature review. Archives of Internal Medicine, 163(20), 2433-2445. 
doi:10.1001/archinte.163.20.2433 
Barnhofer, T., & Crane, C. (2009). Mindfulness-based cognitive therapy for depression and 
suicidality. In F. Didonna, F. Didonna (Eds.), Clinical handbook of mindfulness (pp. 221-
243). New York, NY, US. doi:10.1007/978-0-387-09593-6_13  
Baron, R. M., & Kenny, D. A. (1986). The moderator–mediator variable distinction in social 
psychological research: Conceptual, strategic, and statistical considerations. Journal of 
Personality and Social Psychology, 51(6), 1173-1182. doi:10.1037/0022-3514.51.6.1173 
Bauer, D. J., Preacher, K. J., & Gil, K. M. (2006). Conceptualizing and testing random indirect 
effects and moderated mediation in multilevel models: New procedures and 
recommendations. Psychological Methods, 11(2), 142-163. doi:10.1037/1082-
989X.11.2.142 
Bien, T. (2009). Paradise lost: Mindfulness and addictive behavior. In F. Didonna, (Eds.), 
Clinical handbook of mindfulness (pp. 289-297). New York, NY: Springer. 
doi:10.1007/978-0-387-09593-6_16  
Berger, J. M. (2011). Ethics in pain management and end of life care. In N. Vadivelu, R. D. 
Urman, & R. L. Hines (Eds.), Essentials of pain management (pp. 629-636). New York: 
Springer.  
 76 
 
Bishop, S., Lau, M., Shapiro, S., Carlson, L., Anderson, N., Carmody, J., … Devins, G. (2004). 
Mindfulness: A proposed operational definition. Clinical Psychology: Science and 
Practice, 11(3), 230-241. doi:10.1093/clipsy/bph077 
Black, D. S. (2014). Mindfulness-based interventions: An antidote to suffering in the context of 
substance use, misuse, and addiction. Substance Use & Misuse, 49(5), 487-491. 
doi:10.3109/10826084.2014.860749. 
Bohn, M. J., Babor, T. F., & Kranzler, H. R. (1995). The Alcohol Use Disorder Identification 
Test (AUDIT): Validation of a screening instrument for use in medical settings. Journal 
of Studies on Alcohol, 56(4), 423-432. doi:10.15288/jsa.1995.56.423 
Bohn, M. J., Babor, T. F., & Kranzler, H. R. (1991). Validity of the drug abuse screening test 
(DAST-10) in inpatient substance abusers: Problems of drug dependence. Proceedings of 
the 53rd Annual Scientific Meeting, the Committee on Problems of Drug Dependence 
Inc., DHHS Publication No. (ADM) 92-1888. NIDA Research Monograph, vol. 119. (pp. 
233). Rockville, MD: Department of Health and Human Services.  
Bolton, J. M., Robinson, J., & Sareen, J. (2009). Self-medication of mood disorders with alcohol 
and drugs in the National Epidemiologic Survey on alcohol and related conditions. 
Journal of Affective Disorders, 115(3), 367-375. doi:10.1016/j.jad.2008.10.003 
Brook, P., Pickering, T., & Connell, J. (Eds.). (2011). Oxford handbook of pain management. 
Oxford, UK: Oxford University Press. doi: 10.1093/med/9780199298143.001.0001 
Brown, K. W., & Ryan, R. M. (2003). The benefits of being present: Mindfulness and its role in 
psychological well-being. Journal of Personality and Social Psychology, 84(4), 822– 
848. doi:10.1037/0022-3514.84.4.822 
 77 
 
Brown, K. W., & Ryan, R. M. (2004). Perils and promise in defining and measuring 
mindfulness: Observations from experience. Clinical Psychology: Science and 
Practice, 11(3), 242– 248. doi:10.1093/clipsy.bph078 
Brown, K. W., & Cordon, S. (2009). Toward a phenomenology of mindfulness: Subjective 
experience and emotional correlates. In F. Didonna (Eds.), Clinical handbook of 
mindfulness (pp. 59-81). New York, NY: Springer. doi:10.1007/978-0-387-09593-6_5  
Brown, K. W., Ryan, R. M., & Creswell, J. D. (2007). Mindfulness: Theoretical foundations and 
evidence for its salutary effects. Psychological Inquiry, 18(4), 211–237. 
doi:10.1080/10478400701598298 
Buysse, D. J., Reynolds III, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The 
Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. 
Psychiatry Research, 28(2), 193-213. doi:10.1016/0165-1781(89)90047-4 
Campbell, L. C., Clauw, D. J., & Keefe, F. J. (2003). Persistent pain and depression: A 
biopsychosocial perspective. Biological Psychiatry, 54(3), 399–409. doi:10.1016/S0006-
3223(03)00545-6 
Carey, K., Carey, M., & Chandra, P. (2003). Psychometric evaluation of the Alcohol Use 
Disorders Identification Test and short Drug Abuse Screening Test with psychiatric 
patients in India. Journal of Clinical Psychiatry, 64(7), 767–774.  
Carmody, J., & Baer, R. A. (2008). Relationships between mindfulness practice and levels of 
mindfulness, medical and psychological symptoms and well-being in a mindfulness-
based stress reduction program. Journal of Behavioral Medicine, 31(1), 23-33. 
doi:10.1007/s10865-007-9130-7 
 78 
 
Carlson, L. E., & Brown, K. W. (2005). Validation of the Mindful Attention Awareness Scale in 
a cancer population. Journal of Psychosomatic Research, 58(1), 29-33. 
doi:10.1016/j.jpsychores.2004.04.366 
Carlson, L. E. (2012). Mindfulness-based interventions for physical conditions: A narrative 
review evaluating levels of evidence, International Scholarly Research Notices 
Psychiatry, 2012(2012), 1-21. doi:10.5402/2012/651583 
Castro‐Sánchez, A. M., Matarán‐Peñarrocha, G. A., López‐Rodríguez, M. M., Lara‐Palomo, I. 
C., Arendt‐Nielsen, L., & Fernández‐de‐las‐Peñas, C. (2012). Gender differences in pain 
severity, disability, depression, and widespread pressure pain sensitivity in patients with 
fibromyalgia syndrome without comorbid conditions. Pain Medicine, 13(12), 1639-1647. 
doi:10.1111/j.1526-4637.2012.01523.x 
Cavanagh, K., Strauss, C., Forder, L., & Jones, F. (2014). Can mindfulness and acceptance be 
learnt by self-help?: A systematic review and meta-analysis of mindfulness and 
acceptance-based self-help interventions. Clinical Psychology Review, 34(2), 118-129. 
doi:10.1016/j.cpr.2014.01.001 
Center for Behavioral Health Statistics and Quality. (2015). 2014 national survey on drug use 
and health: detailed tables. Substance Abuse and Mental Health Services Administration, 
Rockville, MD.  
Centers for Disease Control and Prevention. (2016). Chronic disease overview: Chronic 
Diseases: The Leading Causes of Death and Disability in the United States. Retrieved 
from: http://www.cdc.gov/chronicdisease/overview/index.htm#sec1 
Center for Substance Abuse Treatment. (2010). Protracted withdrawal. Substance Abuse 
Treatment Advisory, 9(1), 1-8.  
 79 
 
Christopher, M. S., Christopher, V., & Charoensuk, S. (2009). Assessing “Western” mindfulness 
among Thai Theravāda Buddhist monks. Mental Health, Religion & Culture, 12(3), 303–
314. doi:10.1080/13674670802651487 
Cocco, K. M., & Carey, K. B. (1998). Psychometric properties of the Drug Abuse Screening Test 
in psychiatric outpatients. Psychological Assessment, 10(4), 408–414. doi:10.1037/1040-
3590.10.4.408 
Cohen, J. (1988). Statistical power analysis for the behavioural sciences. Hillsdale, NJ: Erlbaum. 
doi: 10.1126/science.169.3941.167 
Díaz-Marsa, M., Palomares, N., Morón, M., Tajima, K., Fuentes, M. E., López-Ibor, J., & 
Carrasco, J. (2011). Psychological factors affecting response to antidepressant drugs in 
fibromyalgia. Psychosomatics: Journal of Consultation and Liaison Psychiatry, 52(3), 
237-244. doi:10.1016/j.psym.2010.12.014 
Didonna, F. (Ed.). (2009). Clinical handbook of mindfulness. New York: Springer. 
doi:10.1007/978-0-387-09593-6 
Ebrahim, I. O., Shapiro, C. M., Williams, A. J., & Fenwick, P. B. (2013). Alcohol and sleep I: 
Effects on normal sleep. Alcoholism, Clinical and Experimental Research, 37(4), 539-
549. doi:10.1111/acer.12006 
Egli, M., Koob, G. F., & Edwards, S. (2012). Alcohol dependence as a chronic pain disorder. 
Neuroscience and Biobehavioral Reviews, 36(10), 2179-2192. 
doi:10.1016/j.neubiorev.2012.07.010 
Ehrlich, G. E. (2003). Pain is real; fibromyalgia isn't. The Journal of Rheumatology, 30(8), 1666-
1667.  
 80 
 
Fernandez, A. C., Wood, M. D., Stein, L. A. R., & Rossi, J. S. (2014). Measuring mindfulness 
and examining its relationship with alcohol use and negative consequences. Psychology 
of Addictive Behavior, 24(4), 608–616. doi:10.1037/a0021742. 
Field, A. (2013). Discovering statistics using IBM SPSS (4th ed.). London: Sage Publications.  
Fox III, C. J., Hawney, H. A., & Kaye, A. D. (2011). Opioids: Pharmacokinetics and 
pharmacodynamics. In N. Vadivelu, R. D. Urman, & R. L. Hines (Eds.), Essentials of 
pain management (pp. 91-104). New York: Springer. doi: 10.1007/978-0-387-87579-8_7 
Garland, E. L., Schwarz, N. M., Kelly, A., Whitt, A., & Howard, M. O. (2012). Mindfulness-
oriented recovery enhancement for alcohol dependence: Therapeutic Mechanisms and 
Intervention Acceptability. Journal of Social Work Practice in the Addictions, 12(3), 
242–263. doi:10.1080/1533256X.2012.702638 
Garland, E. L. (2013). Mindfulness-oriented recovery enhancement for addiction, stress, and 
pain. Washington, DC: NASW Press.  
Garland, E. L. (2014). Treating chronic pain: the need for non-opioid options. Expert Review of 
Clinical Pharmacology, 7(5), 545-550. doi:10.1586/17512433.2014.928587 
Garland, E. L., & Black, D. S. (2014). Mindfulness for chronic pain and prescription opioid 
misuse: Novel mechanisms and unresolved issues. Substance Use & Misuse, 49(5), 608–
611. doi:10.3109/10826084.2014.852801 
Gardner-Nix, J. (2003). Opioids and chronic pain. Canadian Medical Association 
Journal, 169(9), 904.  
Gardner-Nix, J. (2009). Mindfulness-based stress reduction for chronic pain management. In F. 
Didonna (Ed.), Clinical handbook of mindfulness (pp. 369-382). New York: Springer.  
 81 
 
Giguère, C. É, & Potvin, S. (2016). The Drug Abuse Screening Test preserves its excellent 
psychometric properties in psychiatric patients evaluated in an emergency setting. 
Addictive Behavior, 64, 165-170. doi:10.1016/j.addbeh.2016.08.042. 
Gloster, A. T., Rhoades, H. M., Novy, D., Klotsche, J., Senior, A., Kunik, M., … Stanley, M. A. 
(2008). Psychometric properties of the depression anxiety and stress scale-21 in older 
primary care patients. Journal of Affective Disorders, 110(3), 248–259. 
doi:10.1016/j.jad.2008.01.023 
Goldenberg, D. L., Burckhardt, C., & Crofford, L. (2004). Management of fibromyalgia 
syndrome. Journal of the American Medical Association, 292(19), 2388–2395. 
doi:10.1001/jama.292.19.2388 
Grass, G. W. (2011). Neuropathic pain. In N. Vadivelu, R. D. Urman, & R. L. Hines (Eds.), 
Essentials of pain management (pp. 515-544). New York: Springer. doi: 10.1007/978-0-
387-87579-8_23 
Greeson, J. M. (2009). Mindfulness research update: 2008. Complementary Health Practice 
Review, 14(1), 10-18. doi:10.1177/1533210108329862. 
Grossman, P. (2008). On measuring mindfulness in psychosomatic and psychological research. 
Journal of Psychosomatic Research, 64, 405–408. doi:10.1016/j.jpsychores.2008.02.001  
Grossman, P. (2011). Defining mindfulness by how poorly I think I pay attention during 
everyday awareness and other intractable problems for psychology's (re)invention of 
mindfulness: Comment on Brown et al. (2011). Psychological Assessment, 23(4), 1034-–
1040. doi:10.1037/a0022713  
 82 
 
Grossman, P., Niemann, L., Schmidt, S., & Walach, H. (2004). Mindfulness-based stress 
reduction and health benefits: A meta-analysis. Journal of Psychosomatic Research, 
57(1), 35–43. doi:10.1016/S0022-3999(03)00573-7  
Grossman, P., Tiefenthaler-Gilmer, U., Raysz, A., & Kesper, U. (2007). Mindfulness training as 
an intervention for fibromyalgia: Evidence of postintervention and 3-year follow-up 
benefits in well-being. Psychotherapy and Psychosomatics, 76(4), 226–233. 
doi:10.1159/000101501 
Hadler, N. M. (2003). Fibromyalgia and the medicalization of misery [editorial]. The Journal of 
Rheumatology, 30(8), 1668-1670.  
Hahn, A., Judd, C. M., Hirsh, H. K., & Blair, I. V. (2014). Awareness of Implicit 
Attitudes. Journal of Experimental Psychology. General, 143(3), 1369–1392. doi: 
10.1037/a0035028 
Hayes, A. F. (2009). Beyond Baron and Kenny: Statistical mediation analysis in the new 
millennium. Communication Monographs, 76(4), 408-420. 
doi:10.1080/03637750903310360 
Hayes, A. F. (2013). Introduction to mediation, moderation, and conditional process analysis: A 
regression-based approach. NY: Guilford Press.  
Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (2012). Acceptance and commitment therapy: An 
experiential approach to behavior change. (2nd ed.). New York: The Guilford Press. 
Hayes, S. C., & Wilson, K. G. (2003). Mindfulness: Method and process. Clinical Psychology: 
Science and Practice, 10(2), 161–165. doi:10.1093/clipsy.bpg018 
Henry, J. D., & Crawford, J. R. (2005). The short-form version of the Depression Anxiety Stress 
Scales (DASS-21): Construct validity and normative data in a large non-clinical 
 83 
 
sample. British Journal of Clinical Psychology, 44(2), 227–239. doi: 
10.1348/014466505X29657 
Hofmann, S. G., Sawyer, A. T., Witt, A. A., & Oh, D. (2010). The effect of mindfulness-based 
therapy on anxiety and depression: A meta-analytic review. Journal of Consulting and 
Clinical Psychology, 78(2), 169-183. doi:10.1037/a0018555  
Jones, G. T., Atzeni, F., Beasley, M., Flüss, E., Sarzi-Puttini, P., & Macfarlane, G. J. (2015). The 
prevalence of fibromyalgia in the general population: a comparison of the American 
College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis 
& Rheumatology, 67(2), 568-575. doi:10.1002/art.38905 
Kabat-Zinn J. (1982). An outpatient program in behavioral medicine for chronic pain patients 
based on the practice of mindfulness meditation: Theoretical considerations and 
preliminary results. General Hospital Psychiatry, 4(1), 33-47. doi: 10.1016/0163-
8343(82)90026-3 
Kabat-Zinn J., Lipworth, L., Burney, R., & Sellers, W. (1987). Four-year follow-up of a 
meditation-based program for the self-regulation of chronic pain: Treatment outcomes 
and compliance. The Clinical Journal of Pain, 3(1), 159–173. doi: 10.1097/00002508-
198703010-00010 
Kabat-Zinn, J., Lipworth, L., & Burney, R. (1985). The clinical use of mindfulness meditation 
for the self-regulation of chronic pain. Journal of Behavioral Medicine, 8(2), 163-190. 
doi:10.1007/BF00845519 
Kabat-Zinn, J. (2013). Full catastrophe living: Using the wisdom of your body and mind to face 
stress, pain, and illness. (2nd ed.). New York: Dell Publishing.  
 84 
 
Kabat-Zinn, J. (1994). Wherever you go there you are: Mindfulness meditations in everyday life. 
New York: Hyperion.  
Kabat-Zinn, J. (2003). Mindfulness-based interventions in context: Past, present, and future. 
Clinical Psychology: Science and Practice, 10(2), 144–156. doi: 10.1093/clipsy/bpg016 
Kanaan, R. A., Lepine, J. P., & Wessely, S. C. (2007). The association or otherwise of the 
functional somatic syndromes. Psychosomatic Medicine, 69(9), 855–859. 
doi:10.1097/PSY.0b013e31815b001a 
Kaplan, K. H., Goldenberg, D. L., & Galvin-Nadeau, M. (1993). The impact of a meditation-
based stress reduction program on fibromyalgia. General Hospital Psychiatry, 15(5), 
284–289. doi: 10.1016/0163-8343(93)90020-O 
Karoly, P., Ruehlman, L. S., & Lanyon, R. I. (2005). The Assessment of Adult Health Care 
Orientations: Development and Preliminary Validation of the Multidimensional Health 
Profile-Health Functioning Index (MHP-H) in a National Sample. Journal of Clinical 
Psychology Medical Settings, 12(1), 79-91. doi: 10.1007/s10880-005-0915-y 
Kazdin, A. E. (2007). Mediators and mechanisms of change in psychotherapy research. Annual 
Review of Clinical Psychology, 3, 1-27. doi:10.1146/annurev.clinpsy.3.022806.091432 
Kim, C., Vincent, A., Clauw, D., Luedtke, C., Thompson, J., Schneekloth, T., & Oh, T. (2013). 
Association between alcohol consumption and symptom severity and quality of life in 
patients with fibromyalgia. Arthritis Research & Therapy, 15(42), 1-8. doi: 
10.1186/ar4200 
Kocovski, N. L., & Rector, N. A. (2007). Predictors of post-event rumination related to social 
anxiety. Cognitive Behaviour Therapy, 36(2), 112–122. 
doi:10.1080/16506070701232090 
 85 
 
Kocovski, N. L., Segal, Z. V., & Battista, S. R. (2009). Mindfulness and psychopathology: 
Problem formulation. In F. Didonna (Ed.), Clinical handbook of mindfulness (pp. 85-98). 
New York, NY: Springer. doi: 10.1007/978-0-387-09593-6_6 
Kuyken, W., Byford, S., Byng, R., Dalgleish, T., Lewis, G., Taylor, R., … Evans, A. (2014). 
Update to the study protocol for a randomized controlled trial comparing mindfulness-
based cognitive therapy with maintenance anti-depressant treatment depressive 
relapse/recurrence: The PREVENT trial. Trials, 15(217), 1-3. doi:10.1186/1745-6215-15-
217 
Kuyken, W., Byford, S., Byng, R., Dalgleish, T., Lewis, G., Taylor, R., … Evans, A. (2010). 
Study protocol for a randomized controlled trial comparing mindfulness-based cognitive 
therapy with maintenance anti-depressant treatment in the prevention of depressive 
relapse/recurrence: The PREVENT trial. Trials, 11(99), 1-10. doi:10.1186/1745-6215-11-
99 
Lauche, R., Cramer, H., Dobos, G., Langhorst, J., & Schmidt, S. (2013). A systematic review 
and meta-analysis of mindfulness-based stress reduction for the fibromyalgia 
syndrome. Journal of Psychosomatic Research, 75(6), 500-510. 
doi:10.1016/j.jpsychores.2013.10.010 
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., … Wolfe, 
F. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the 
United States, part II. Arthritis Rheumatology, 58(1), 26–35. doi:10.1002/art.23176 
Leigh, J., Bowen, S., & Marlatt, G. A. (2005). Spirituality, mindfulness, and substance abuse. 
Addictive Behavior, 30(7), 1335-1341. doi:10.1016/j.addbeh.2005.01.010 
 86 
 
Leigh, J., & Neighbors, C. (2009). Enhancement Motives Mediate the Positive Association 
Between Mind/Body Awareness and College Student Drinking. Journal of Social and 
Clinical Psychology, 28(5), 650–669. doi: 10.1521/jscp.2009.28.5.650 
Leo, R. J., Quinton, W. J., & Ebert, M. H. (2011). Psychological and psychosocial evaluation of 
the chronic pain patient. In N. Vadivelu, R. D. Urman, & R. L. Hines (Eds.), Essentials of 
pain management (pp. 203-237). New York: Springer.  
Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the Depression Anxiety Stress Scales. 
(2nd ed.). Sydney: Psychology Foundation.  
Malin, K., & Littlejohn, G. (2012). Psychological control is a key modulator of fibromyalgia 
symptoms and comorbidities. Journal of Pain Research, 5, 463–471. 
doi:10.2147/JPR.S37056 
Manocchia, M., Keller, S., & Ware, J. E. (2001). Sleep problems, health-related quality of life, 
work functioning and health care utilization among the chronically ill. Quality of Life 
Research, 10(4), 331-345. doi:10.1023/A:1012299519637 
Marlatt, G. A., & Kristeller, J. L. (1999). Mindfulness and meditation. In W. R. Miller (Ed.), 
Integrating spirituality into treatment: Resources for practitioners (pp. 67-84). 
Washington, DC: American Psychological Association. doi: 10.1037/10327-004 
McCoach, B. D., Gable, R. K., & Madura, J. P. (2013). Instrument development in the affective 
domain. (3rd ed.). Social and Corporate Applications: Springer.  
McHorney, C. A., Ware, J. E., Lu, J. F. R., & Sherbourne, C. D. (1994). The MOS 36-Item 
short-form health survey (SF-36®): III. Tests of data quality, scaling assumptions and 
reliability across diverse patient groups. Medical Care, 32(1), 40-66.  
 87 
 
McHorney, C. A., Ware, J. E., & Raczek, A. E. (1993). The MOS 36-item short-form health 
survey (SF-36®): II. Psychometric and clinical tests of validity in measuring physical and 
mental health constructs. Medical Care, 31(3), 247-263. doi: 10.1097/00005650-
199303000-00006 
Marcus, D., & Deodhar, A. (2011a). Fibromyalgia definition and epidemiology. Fibromyalgia: A 
practical clinical guide (pp. 9-21). New York: Springer.  
Marcus, D., & Deodhar, A. (2011b). Pathophysiology of fibromyalgia. Fibromyalgia: A 
practical clinical guide (pp. 23-39). New York: Springer.  
Marcus, D., & Deodhar, A. (2011c). Depression and anxiety. Fibromyalgia: A practical clinical 
guide (pp. 115-122). New York: Springer.  
Melzack, R. (1999). From the gate to the neuromatrix. Pain, S6, S121–S126. doi:10.1016/S0304-
3959(99)00145-1 
Meneses-Gaya, C., Zuardi, A. W., Loureiro, S. R., & Crippa, J. S. (2009). Alcohol use disorders 
identification test (AUDIT): An updated systematic review of psychometric properties. 
Psychology & Neuroscience, 2(1), 83-97. doi:10.3922/j.psns.2009.1.12 
Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: Helping people change. (3rd 
ed.). New York, NY: Guilford Press. doi: 10.1080/02615479.2014.894351 
Mirchandani, A., Saleeb, M., & Sinatra, R. (2011). Acute and chronic mechanisms of pain. In N. 
Vadivelu, R. D. Urman, & R. L. Hines (Eds.), Essentials of pain management (pp. 45-
54). New York: Springer.  
Morone, N. E., Lynch, C. S., Greco, C. M., Tindle, H. A., & Weiner, D. K. (2008). I Feel Like a 
New Person. The effects of mindfulness meditation on older adults with chronic pain: A 
 88 
 
qualitative narrative analysis of diary entries. Journal of Pain, 9, 841–848. doi: 
10.1016/j.pain.2008.04.003 
Murphy, L., Ng, K. W. K., Su, V. C., Woodworth-Giroux, S., Levy, T. S., Sproule, B. A., Furlan, 
A. D. (2015). Approach to the pharmacological management of chronic pain in patients 
with an alcohol use disorder. Journal of Pain Research, 8, 851-857. 
doi:10.2147/JPR.S88900.eCollection 2015. 
National Institute on Alcohol Abuse and Alcoholism. (2015). Overview of alcohol consumption. 
Retrieved from: http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-
consumption/moderate-binge-drinking  
National Institute on Alcohol Abuse and Alcoholism. (2013). Drinking levels defined. Retrieved 
from: http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-
facts-and-statistics  
Nolen-Hoeksema, S. (2000). The role of rumination in depressive disorders and mixed 
anxiety/depressive symptoms. Journal of Abnormal Psychology, 109(3), 504-511.  
Nolen-Hoeksema, S. (2012). Emotion regulation and psychopathology: The role of 
gender. Annual Review of Clinical Psychology, 8, 161-187. doi:10.1146/annurev-clinpsy-
032511-143109 
Nolen-Hoeksema, S., Desrosiers, A., & Wilsnack, S. C. (2013). Predictors of alcohol-related 
problems among depressed and non-depressed women. Journal of Affective Disorders, 
150(3), 967-973. doi:10.1016/j.jad.2013.05.022 
Nolen-Hoeksema, S., Harrell, Z. A. (2002). Rumination, depression, and alcohol use: Tests of 
gender differences. Journal of Cognitive Psychotherapy: An International Quarterly, 
16(4), 391-403. doi: 10.1891/jcop.16.4.391.52526 
 89 
 
Painter, J. T., & Crofford, L. J. (2013). Chronic opioid use in fibromyalgia syndrome: A clinical 
review. Journal of Clinical Rheumatology, 19(2), 72-77. doi: 
10.1097/RHU.0b013e3182863447. 
Park, T., Reilly-Spong, M., & Gross, C. R. (2013). Mindfulness: A systematic review of 
instruments to measure an emergent patient-reported outcome (PRO). Quality of Life 
Research, 22(10), 2639-2659. doi: 10.1007/s11136-013-0395-8 
Parra-Delgado, M., & Latorre-Postigo, J. (2013). Effectiveness of mindfulness-based cognitive 
therapy in the treatment of fibromyalgia: A randomised trial. Cognitive Therapy And 
Research, 37(5), 1015-1026. doi:10.1007/s10608-013-9538-z 
Passik, S. D., & Kirsh, K. L. (2008). The interface between pain and drug abuse and the 
evolution of strategies to optimize pain management while minimizing drug abuse. 
Experimental and Clinical Psychopharmacology, 16(5), 400-404. doi:10.1037/a0013634. 
Patten, S. B., Beck, C. A., Kassam, A., Williams, J. V., Barbui, C., & Metz, L. M. (2005). Long-
term medical conditions and major depression: strength of association for specific 
conditions in the general population. Canadian Journal of Psychiatry, 50(4), 195-202. 
doi:10.1177/070674370505000402 
Pearson, M. R., Brown, D. B., Bravo, A. J., & Witkiewitz, K. (2015). Staying in the moment and 
finding purpose: The associations of trait mindfulness, decentering, and purpose in life 
with depressive symptoms, anxiety symptoms, and alcohol-related problems. 
Mindfulness, 6(3), 1-9. doi:10.1007/s12671-014-0300-8 
Perl, E. R. (2007). Ideas about pain, a historical review. National Review of Neuroscience, 8(1), 
71-80. doi:10.1038/nrn2042 
 90 
 
Pettinati, H. M., & Dundon, W. D. (2011). Comorbid depression and alcohol dependence. 
Psychiatric Times, 28(6), 1-8.  
Preacher, K. J., & Hayes, A. F. (2008a). Asymptotic and resampling strategies for assessing and 
comparing indirect effects in multiple mediator models. Behavior Research Methods, 
40(3), 879-891. doi:10.3758/BRM.40.3.879 
Preacher, K. J., & Hayes, A. F. (2008b). Contemporary approaches to assessing mediation in 
communication research. In A. F. Hayes, M. D. Slater, & L. B. Snyder (Eds.), The Sage 
sourcebook of advanced data analysis methods for communication research (pp. 13-54). 
Thousand Oaks, CA: Sage Publications. doi:10.4135/9781452272054.n2 
Preacher, K. J., Rucker, D. D., & Hayes, A. F. (2007). Addressing moderated mediation 
hypotheses: Theory, methods, and prescriptions. Multivariate Behavioral Research, 
42(1), 185-227. doi:10.1080/00273170701341316 
Radat, F., Margot-Duclot, A., & Attal, N. (2013). Psychiatric co-morbidities in patients with 
chronic peripheral neuropathic pain: A multicentre cohort study. European Journal of 
Pain, 17(10), 1547–1557. doi:10.1002/j.1532-2149.2013.00334.x 
Redelmeier, D. A., Zung, J. D., Thiruchelvam, D., & Tibshirani, R. J. (2015). Fibromyalgia and 
the risk of a subsequent motor vehicle crash. The Journal of Rheumatology, 42(8), 1502-
1510. doi:10.3899/jrheum.141315 
Riddle, D. L., Kong, X., & Fitzgerald, G. K. (2011). Psychological health impact on 2-year 
changes in pain and function in persons with knee pain: Data from the osteoarthritis 
initiative. Osteoarthritis Cartilage, 19(9), 1095–1101. doi:10.1016/j.joca.2011.06.003 
Riley, J. L., III, & King, C. (2009). Self-report of alcohol use for pain in a multi-ethnic 
community sample. Journal of Pain, 10(9), 944–952. doi:10.1016/j.jpain.2009.03.005 
 91 
 
Roehrs, T., & Roth, T. (2001). Sleep, sleepiness, and alcohol use. Sleep Medicine Review, 5(4), 
287-297. doi: 10.1053/smrv.2001.0162 
Ruta, D. A., Abdalla, M. I., Garratt, A. M., Coutts, A., & Russell, I. T. (1994). SF 36 health 
survey questionnaire: I. Reliability in two patient based studies. Quality in Health 
Care, 3(4), 180–185. doi: 10.1136/qshc.3.4.180 
Sanders, G. L., Sprintz, M. P., Ellender, R. P., Sabartinelli, A. L., & Kaye, A. D. (2011). 
Opioids: Basic concepts in clinical practice. In N. Vadivelu, R. D. Urman, & R. L. Hines 
(Eds.), Essentials of pain management (pp. 105-116). New York: Springer.  
Savage, S. R., Kirsh, K. L., & Passik, S. D. (2008). Challenges in using opioids to treat pain in 
persons with substance use disorders. Addiction Science & Clinical Practice, 4(2), 4–25. 
Schmidt, S., Grossman, P., Schwarzer, B., Jena, S., Naumann, J., & Walach, H. (2011). Treating 
fibromyalgia with mindfulness-based stress reduction: results from a 3-armed 
randomized controlled trial. Pain, 152(2), 361-369. doi:10.1016/j.pain.2010.10.043  
Segal, Z. V., Williams, J. M., & Teasdale, J. D. (2013). Mindfulness-based cognitive therapy for 
depression: A new approach to preventing relapse (2nd ed.). New York: The Guildford 
Press.  
Sephton, S. E., Salmon, P., Weissbecker, I., Ulmer, C., Floyd, A., Hoover, K., Studts, J. (2007). 
Mindfulness meditation alleviates depressive symptoms in women with fibromyalgia: 
Results of a randomized clinical trial. Arthritis & Rheumatism (Arthritis Care & 
Research), 57(1), 77– 85. doi 10.1002/art.22478 
Serxner, S. (2013). A different approach to population health and behavior change: Moving from 
incentives to a motivation-based approach. American Journal of Health Promotion/The 
Art of Health Promotion, 27(4), 4-7.  
 92 
 
Singh, A. (2012). Pain behaviors and psychiatric complications in pain syndrome. International 
Medical Journal, 19(3), 205-207.  
Shapiro, S. L., Carlson, L. E., Astin, J. A., & Freedman, B. (2006). Mechanisms of mindfulness. 
Journal of Clinical Psychology, 62(3), 373-386. doi:10.1002/jclp.20237 
Skinner, H. (1982). The Drug Abuse Screening Test. Addictive Behaviors, 7(4), 363–371.  
Song, Y., Lu, H., Chen, H., Geng, G., & Wang J. (2014). Mindfulness intervention in the 
management of chronic pain and psychological comorbidity: A meta-analysis. 
International Journal of Nursing Sciences, 1(2), 215-223. 
doi:10.1016/j.ijnss.2014.05.014 
Staud, R. (2011). Sodium oxybate for the treatment of fibromyalgia. Expert Opinion 
Pharmacotherapy, 12(11), 1789-1798. doi:10.1517/14656566.2011.589836  
Steiner, J. L., Bigatti, S. M., & Ang, D. C. (2015). Trajectory of change in pain, depression, and 
physical functioning after physical activity adoption in fibromyalgia. Journal of Health 
Psychology, 20(7), 931–941. doi:10.1177/1359105313504234  
Treadway, M. T., & Lazar, S. W. (2009). The neurobiology of mindfulness. In F. Didonna (Ed.), 
Clinical handbook of mindfulness (pp. 45-57). New York: Springer.  
Vadivelu, N., & Urman, R. D. (2011). Fibromyalgia, arthritic, and myofascial pain. In N. 
Vadivelu, R. D. Urman, & R. L. Hines (Eds.), Essentials of pain management (pp. 557-
566). New York: Springer.  
Vadivelu, N., Urman, R. D., & Hines, R. L. (Eds.). (2011). Essentials of pain management. New 
York: Springer. :doi10.1007/978-0-387-87579-8 
Wagner, J. S., DiBonaventura, M. D., Chandran, A. B., & Cappelleri, J. C. (2012). The 
association of sleep difficulties with health-related quality of life among patients with 
 93 
 
fibromyalgia. BMC Musculoskeletal Disorders, 13(1), 199. doi:10.1186/1471-2474-13-
199 
Ware, J. E., Jr., Kosinski, M., Bjorner, J. B., Turner–Bowker, D. M., Gandek, B., & Maruish, M. 
E. (2007). User’s Manual for the SF-36v2 ® Health Survey (2nd ed.). Lincoln, RI: Quality 
Metric Incorporated.  
Webb, J. R., Phillips, T. D., Bumgarner, D., & Conway-Williams, E. (2013). Forgiveness, 
mindfulness, and health. Mindfulness, 4(3), 191-202. doi:10.1007/s12671-012-0119-0 
Weinstein, N., Brown, K. W., & Ryan, R. M. (2009). A multi-method examination of the effects 
of mindfulness on stress attribution, coping, and emotional well-being. Journal of 
Research in Personality, 43(3), 374-385. doi:10.1016/j.jrp.2008.12.008 
Wells, K. B., Burnam, M. A., Rogers, W., Hays, R., & Camp, P. (1992). The course of 
depression in adult outpatients: results from the Medical Outcomes Study. Archive of 
General Psychiatry, 49(10), 788-794. doi:10.1001/archpsyc.1992.01820100032007 
Williams, M., Teasdale, J.D., Segal, Z., & Kabat-Zinn, J. (2007). The mindful way through 
depression: Freeing yourself from chronic unhappiness. New York, NY: The Guilford 
Press. 
Wolfe, F., Clauw, D., Fitzcharles, M., Goldenberg, D., Katz, R., Mease, P., … Yunus, M. B. 
(2010). The American College of Rheumatology preliminary diagnostic criteria for 
fibromyalgia and measurement of symptom severity. Arthritis Care & Research 
(Hoboken), 62(5), 600–610. doi:10.1002/acr.20140. 
Wolfe, F., Walitt, B. T., Katz, R. S., Lee, Y. C., Michaud, K. D., & Häuser, W. (2013). 
Longitudinal patterns of analgesic and central acting drug use and associated 
 94 
 
effectiveness in fibromyalgia. European Journal of Pain, 17(4), 581-586. 
doi:10.1002/j.1532-2149.2012.00234.x 
World Health Organization (1946). Preamble to the Constitution of the World Health 
Organization as adopted by the International Health Conference. Retrieved from: World 
Health Organization (1946). Preamble to the Constitution of the World Health 
Organization as adopted by the International Health Conference. Retrieved from: 
http://www.who.int/about/mission/en/  
Yudko, E., Lozhkina, O., & Fouts, A. (2007). A comprehensive review of the psychometric 
properties of the Drug Abuse Screening Test. Journal of Substance Abuse Treatment, 
32(2), 189-198. doi:10.1016/j.jsat.2006.08.002 
Zale, E. L., Maisto, S. A., & Ditre, J. W. (2015). Interrelations between pain and alcohol: An 
integrative review. Clinical Psychology Review, 37, 57-71. doi:10.1016/j.cpr.2015.02.005 
Zeidan, F., Martucci, K., Kraft, R., Gordon, F., McHaffie, J., & Coghill, R. (2011). Brain 
mechanisms supporting modulation of pain by mindfulness meditation. Journal of 
Neuroscience, 31(14), 5540–5548. doi:10.1523/JNEUROSCI.5791-10.2011 
 
 
 
 
 
 
 
 
 
 
 
 95 
 
VITA 
 
JULIE I. MORRISSEY 
   
 
Professional Experience:  Behavioral Health Provider, ETSU College of Nursing, Johnson  
City Downtown Day Center, 2016- Present 
 
Behavioral Health Provider, ETSU Behavioral Health and 
Wellness Clinic, 2015-2017 
 
Education:   M. A. Clinical Psychology, East Tennessee State University,  
Johnson City, Tennessee 2017  
 
Federally Recognized, Ordained Minister, Studied Metaphysics, 
Spirituality, & Divinity, Alliance of Divine Love Ministerial 
Program, Mill Spring, North Carolina 2014 
   
Notable Research: Morrissey, J. I., Nsamenang S. A., Mitchell, K., Sirois, F. M., & 
Hirsch, J. K. (2014). Fatigue and treatment control in patients with 
multiple sclerosis: trait hope as a moderator. Presented at the 122th 
annual conference of the American Psychological Association, 
Washington D.C. Acknowledgement: Research conducted was 
funded by SAMHSA GLS Grant 1U79SM058957-01. 
 
Morrissey, J. I., Brudecki, L. E. & Elgazzar, M. (2013). Ethyl 
Pyruvate restores transcription, but not protein synthesis, of 
inflammatory genes in a cell model of severe systemic 
inflammation. Presented at the Posters at the Capitol, hosted by 
The ETSU’s Honors College, Nashville, TN. 
 
Honors and Awards:  Quillen Scholar Award, East Tennessee State University, 2014-
2017 
   
Academic Tuition Waiver and Stipend Grant, Clinical Psychology 
Graduate Program, East Tennessee State University 2013-2017  
 
Funded Independent Research Study Grant, East Tennessee State 
University, Honors College 2012
